ALL test with LOT rules and updated questions

What ICD-10-CM diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., Z85) variants?

The supplied documents identify ICD-10-CM codes for Acute lymphoblastic leukemia (ALL) and remission/relapse states. The CMS ICD-10-CM release files list "C9100 — Acute lymphoblastic leukemia not having achieved remission," "C9101 — Acute lymphoblastic leukemia, in remission," and "C9102 — Acute lymphoblastic leukemia, in relapse" under "C910 — Acute lymphoblastic leukemia all." The NLM Clinical Tables additionally define ICD-10-CM code C91.01 as "Acute lymphoblastic leukemia, in remission" and ICD-10-CM code C91.02 as "Acute lymphoblastic leukemia, in relapse." The documents do not provide codes or conventions for refractory disease, secondary malignancy involvement, personal-history Z85 codes, or suspected versus confirmed diagnosis coding. The supplied documents identify ICD-9-CM acute lymphoid leukemia diagnosis codes for three disease-status categories: active disease without remission, remission, and relapse. Specifically, code 20400 is defined as "Acute lymphoid leukemia, without mention of having achieved remission," code 20401 as "Acute lymphoid leukemia, in remission," and code 20402 as "Acute lymphoid leukemia, in relapse." The documents do not provide ICD-10-CM diagnosis codes, refractory disease codes, secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents identify ICD-9-CM leukemia codes for subacute lymphoid leukemia with distinct disease-status modifiers relevant to claims classification. Specifically, code 20420 is defined as "Subacute lymphoid leukemia, without mention of having achieved remission," code 20421 as "Subacute lymphoid leukemia, in remission," and code 20422 as "Subacute lymphoid leukemia, in relapse." The documents do not provide ICD-10-CM diagnosis codes, refractory disease codes, secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents only identify ICD-9-CM lymphoid leukemia remission and relapse codes, not ICD-10-CM Acute Lymphoblastic Leukemia coding through 2026-09-21. The documents include code 20481 for “Other lymphoid leukemia, in remission,” code 20482 for “Other lymphoid leukemia, in relapse,” and code 20492 for “Unspecified lymphoid leukemia, in relapse.” The documents do not provide ICD-10-CM active disease codes, remission variants for ALL, refractory disease coding, secondary malignancy involvement codes, personal-history Z85 codes, or suspected-versus-confirmed diagnosis coding conventions. The supplied documents identify one ICD-10-CM code for active Acute Lymphoblastic Leukemia and one historical leukemia code from ICD-9-CM. ICD-10-CM code C91.00 is defined as "Acute lymphoblastic leukemia not having achieved remission." The documents also include ICD-9-CM code V1061, defined as "Personal history of lymphoid leukemia." The documents do not provide ICD-10-CM remission variants beyond not having achieved remission, relapse or refractory codes, secondary malignancy codes, ICD-10-CM personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents do not provide United States ICD-10-CM diagnosis codes, remission variants, relapse or refractory codes, secondary malignancy codes, personal-history Z85 codes, or suspected-versus-confirmed coding conventions for Acute Lymphoblastic Leukemia. The only coding information provided is an ICD-9-CM entry stating that code 20491 is defined as "Unspecified lymphoid leukemia, in remission." The supplied documents identify the primary ICD-10-CM Acute Lymphoblastic Leukemia (ALL) code family as C91.0 and provide specific 2026 billable diagnosis codes for active disease, remission, and relapse states: C91.00 "Acute lymphoblastic leukemia not having achieved remission," C91.01 "Acute lymphoblastic leukemia, in remission," and C91.02 "Acute lymphoblastic leukemia, in relapse." The documents also state that C91.00 is applicable to "Acute lymphoblastic leukemia with failed remission" and "Acute lymphoblastic leukemia NOS," which addresses refractory/failed-remission disease terminology within claims coding. The supplied materials do not provide specific ICD-10-CM secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions distinguishing suspected versus confirmed ALL diagnoses.

CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web

What CPT and HCPCS codes cover bone marrow biopsy, aspiration and flow cytometry in ALL?

The supplied documents identify one HCPCS code for a combined bone marrow aspiration and biopsy procedure, one HCPCS code for a powered bone marrow biopsy needle device, and one LOINC code for a flow cytometry study. Specifically, HCPCS code G0364 is defined as "Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service." HCPCS code C1830 is defined as "Powered bone marrow biopsy needle." The documents also include LOINC code 33719-6 for a "Flow cytometry study." The documents do not provide CPT codes, additional bone marrow biopsy or aspiration procedure codes, hematopathology service codes, or information specific to monitoring procedure use in Acute Lymphoblastic Leukemia. The supplied documents identify LOINC entries related to bone marrow biopsy, bone marrow aspiration, and flow cytometry review, but they do not provide CPT or HCPCS procedure codes. The documents include LOINC 33721-2 for a "Bone marrow Pathology biopsy report," LOINC 48807-2 for a "Bone marrow aspiration report," and LOINC 69052-9 for "Flow cytometry specialist review of results." No documents describe hematopathology CPT/HCPCS services or monitoring procedure-use coding for Acute Lymphoblastic Leukemia claims data. The supplied document does not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, flow cytometry, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia claims data. It only identifies a LOINC entry related to bone marrow aspiration guidance: LOINC code 87008-9, defined as "Guidance for fluid aspiration of Bone marrow." The supplied document only identifies a LOINC laboratory concept related to flow cytometry and does not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia. The document states that LOINC code 61126-9 is defined as "Blasts/cells in Specimen by Flow cytometry (FC)." The supplied documents do not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia. The only procedure-related coding information provided is a LOINC entry for flow cytometry: LOINC code 107079-6, defined as "Blasts/Cells in Blood by Flow cytometry (FC)." It only identifies a flow cytometry-related laboratory concept: LOINC code 54226-6, defined as "Lymphoma panel - Specimen by Flow cytometry (FC)."

U.S. National Library of Medicine

What CPT and LOINC codes cover cytogenetic and molecular testing relevant to ALL?

The supplied documents identify three LOINC laboratory codes relevant to flow cytometry testing that may be used in hematologic malignancy evaluation and monitoring. The documents provide LOINC code 61126-9 for "Blasts/cells in Specimen by Flow cytometry (FC)", LOINC code 69052-9 for "Flow cytometry specialist review of results", and LOINC code 54226-6 for "Lymphoma panel - Specimen by Flow cytometry (FC)". The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or ALL-specific monitoring assay coding beyond these LOINC entries. The supplied documents identify several LOINC laboratory mappings relevant to hematologic evaluation and monitoring. LOINC code 61123-6 is defined as "Lymphocytes/Leukocytes in Specimen by Flow cytometry (FC)." Additional LOINC mappings include 33721-2 for a "Bone marrow Pathology biopsy report" and 48807-2 for a "Bone marrow aspiration report." The documents do not provide CPT codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or specific monitoring assay CPT mappings for Acute Lymphoblastic Leukemia classification or risk stratification. The supplied documents identify three LOINC laboratory codes relevant to flow cytometry and leukemia-related laboratory assessment. LOINC 30912-0 is defined as "DNA index in Specimen by Flow cytometry (FC)." LOINC 33719-6 is defined as "Flow cytometry study," and LOINC 107079-6 is defined as "Blasts/Cells in Blood by Flow cytometry (FC)." The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay CPT mappings for Acute Lymphoblastic Leukemia. The supplied documents identify two LOINC laboratory codes potentially relevant to Acute Lymphoblastic Leukemia evaluation and monitoring. LOINC 66119-9 is defined as "Bone marrow Pathology biopsy report Narrative," and LOINC 30364-4 is defined as "Lymphocytes [#/volume] in Blood by Flow cytometry (FC)." The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or specific monitoring assay code sets for ALL classification or risk stratification. The supplied documents only identify one LOINC laboratory mapping relevant to flow cytometry testing. LOINC code 101147-7 is defined as "Monocytes/Leukocytes in Blood by Flow cytometry (FC)." No CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay codes specific to Acute Lymphoblastic Leukemia classification, risk stratification, or monitoring are provided in the documents. The supplied documents only identify one LOINC laboratory code related to flow cytometry and do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay mappings for Acute Lymphoblastic Leukemia. The available document states that LOINC code 104548-3 corresponds to "Monocytes [#/volume] in Blood by Flow cytometry (FC)." The supplied documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay codes relevant to Acute Lymphoblastic Leukemia. The only laboratory mapping identified is the LOINC code 26028-1, defined as "HLA-B27 presence by Flow cytometry (FC)." The documents identify several CPT codes for fluorescence in situ hybridization (FISH) testing relevant to Acute Lymphoblastic Leukemia (ALL): "CPT Code(s): 88237, 88275 (x per analyses), 88271 (x per probe)." The FISH panels include genomic targets used for ALL classification, prognostic assessment, and monitoring, including "t(9;22) (BCR/ABL1), 11q23.3 (KMT2A, formerly MLL), t(12;21) (ETV6/RUNX1)," as well as CRLF2, ABL1, ABL2, PDGFRB, PBX1;TCF3, and CDKN2A. The documents also state that "FISH is useful to identify chromosome abnormalities in patients with pediatric or adult acute lymphoblastic leukemia (ALL) for diagnostic and prognostic purposes as well as for follow-up to evaluate patient response to therapy" and that "Companion testing with chromosome analysis is recommended." No LOINC codes, specific cytogenetic chromosome analysis CPT codes beyond the listed FISH-related CPTs, or broader molecular pathology/genomic laboratory billing codes are provided in the supplied documents.

U.S. National Library of MedicineOpen web

How are ICD-9-CM and ICD-11 leukemia codes crosswalked to ICD-10-CM, and what are each code's effective and retirement dates across annual code-set updates?

The supplied documents identify ICD-9-CM legacy Acute Lymphoid Leukemia diagnosis codes and one ICD-10-CM Acute Lymphoblastic Leukemia concept. ICD-9-CM code 20401 is defined as "Acute lymphoid leukemia, in remission," and ICD-9-CM code 20402 is defined as "Acute lymphoid leukemia, in relapse." The CMS ICD-10-CM release file excerpt lists ICD-10-CM concept C910 "Acute lymphoblastic leukemia all" with subcode C9100 "Acute lymphoblastic leukemia not having achieved remission." The documents do not provide ICD-9-CM to ICD-10-CM crosswalk mappings, ICD-11 stem or extension codes, linkage rules, or effective, revision, and retirement dates across annual coding updates. The supplied documents identify two ICD-10-CM concepts for Acute Lymphoblastic Leukemia. ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission," and ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse." The documents do not provide ICD-9-CM legacy leukemia mappings, ICD-11 stem or extension code mappings, linkage information, or any effective, revision, or retirement dates across annual coding updates. The supplied documents identify ICD-10-CM concepts for Acute Lymphoblastic Leukemia (ALL) and provide some annual update and effective-date information, but they do not provide ICD-9-CM legacy leukemia code mappings, ICD-11 stem-code mappings, ICD-11 extension-code linkage, or retirement-date histories. The documents state that “The ICD-10 code for acute lymphoblastic leukemia is C91.0, with specific codes for remission status,” and list the ICD-10-CM remission-status concepts “C91.00,” “C91.01,” and “C91.02.” The 2026 ICD-10-CM update documentation states that “The 2026 edition of ICD-10-CM C91.00 became effective on October 1, 2025,” and displays annual code-set continuity for “20162017201820192020202120222023202420252026.” No supplied document contains ICD-9-CM to ICD-10-CM crosswalks, ICD-11 mappings, revision histories beyond the cited annual editions, or retirement dates.

CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web

Which ICD-11 extension codes express ALL molecular subtypes on the disease stem?

Not answered from the sources consulted.

What procedure codes identify non-drug anti-cancer treatments for ALL, such as radiation, stem cell transplant, and CAR-T?

The supplied documents identify Acute Lymphoblastic Leukemia diagnosis coding, including ICD-10-CM code C91.0 and related remission-status codes C91.00, C91.01, and C91.02. The documents also mention that ALL treatment can include “radiation therapy” and “stem cell transplant,” but they do not provide CPT, HCPCS, ICD-10-PCS, leukapheresis, cellular collection, conditioning regimen, CAR-T administration, or specific procedure codes requested in the question.

Open web

Which drug administration codes (e.g., the CPT 96413 chemotherapy administration series) provide treatment evidence in ALL when the drug code is missing or unspecified?

Not answered from the sources consulted.

Which codes identify clinical trial participation in ALL (e.g., Z00.6, Q0/Q1 modifiers)?

The supplied documents identify ICD-10-CM diagnosis codes for Acute Lymphoblastic Leukemia (ALL), including remission and relapse status codes. However, the documents do not provide any information on clinical trial diagnosis codes, HCPCS modifiers such as Q0 or Q1, investigational service indicators, routine clinical trial care billing indicators, or revenue code markers for claims-based line-of-therapy analyses. The supplied documents only identify one Acute Lymphoblastic Leukemia diagnosis code: ICD-10-CM code C91.02, defined as “Acute lymphoblastic leukemia, in relapse.” The documents do not provide any information on clinical trial diagnosis codes, HCPCS modifiers Q0 or Q1, investigational service indicators, routine trial care billing markers, or revenue code indicators for claims-based line-of-therapy analyses. The supplied documents identify one Acute Lymphoblastic Leukemia diagnosis code relevant to claims-based analyses: ICD-10-CM code C91.00, defined as “Acute lymphoblastic leukemia not having achieved remission.” The documents do not provide information on clinical trial diagnosis codes, HCPCS modifiers Q0 or Q1, investigational service indicators, routine trial care billing, or revenue code markers. The supplied documents do not provide the requested diagnosis codes, HCPCS modifiers such as Q0 and Q1, revenue codes, investigational service indicators, or routine clinical trial billing markers specific to claims-based line-of-therapy analyses in Acute Lymphoblastic Leukemia patients. The documents only establish that HCPCS includes categories related to “Administrative, Miscellaneous and Investigational” services and that CMS maintains annually updated CPT/HCPCS code lists through 2026. No document in the set identifies specific clinical trial participation diagnosis codes, Q0/Q1 modifier definitions, or revenue code indicators for investigational or routine trial-related care.

CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web

How are lines of therapy defined for ALL in real-world claims research?

The supplied document contains treatment-cycle and interruption rules for BESPONSA in relapsed or refractory acute lymphoblastic leukemia, including cycle start timing, dose scheduling, interruption thresholds, and hematopoietic stem cell transplant (HSCT) considerations. It states that "Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity," and that subsequent cycles are "4 weeks in duration." The document also specifies interruption and discontinuation logic, including that clinicians should "interrupt the next cycle of treatment until recovery" for specified hematologic toxicities and that "Greater than 28 days" of interruption may require to "Consider permanent discontinuation of treatment." For HSCT handling, it states that "For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles," with a possible third cycle under defined response conditions. The document does not provide United States claims-data operational algorithms for constructing lines of therapy, including regimen-level line advancement triggers, treatment-gap definitions in claims data, maintenance handling, relapse/re-treatment episode construction, or claims-based transplant episode logic. The supplied document does not describe United States claims-data algorithms for constructing lines of therapy in Acute Lymphoblastic Leukemia, including regimen start/stop logic, line advancement triggers, treatment gaps, maintenance handling, stem-cell transplant episode handling, or relapse/retreatment operational rules. It only provides BLINCYTO treatment-cycle schedules and interruption rules that mention induction, consolidation, continued therapy, treatment-free intervals, and restarting cycles after interruptions. Specifically, the document states that induction and consolidation cycles are "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval," while "continued therapy consists of 28 days of continuous intravenous infusion followed by a 56-day treatment-free interval." It also states that "If the interruption after an adverse reaction is no longer than 7 days, continue the same cycle," but "If an interruption due to an adverse reaction is longer than 7 days, start a new cycle."

National Library of Medicine (DailyMed)

What are the standard multi-agent induction, consolidation and maintenance regimens for ALL?

The supplied documents do not provide a comprehensive United States claims-based regimen library for Acute Lymphoblastic Leukemia (ALL), and they do not enumerate induction, consolidation, intensification, maintenance, or detailed multi-agent regimen sequencing groupings and aliases. The documents do identify several ALL-related therapeutic agents and cellular therapies that may appear in regimen libraries, including “rituximab,” “blinatumomab,” “inotuzumab ozogamicin,” “vincristine sulfate,” “doxorubicin hydrochloride,” “cyclophosphamide,” “methotrexate sodium,” “cytarabine,” “daunorubicin hydrochloride,” “Tisagenlecleucel CAR-T,” and “Brexucabtagene autoleucel CAR-T.” The transplantation-related document states that “Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission,” and also notes that “chemotherapy + imatinib” had outcomes “comparable for allogeneic SCT.” No document supplies standardized regimen aliases, naming conventions, or component-grouping rules for treatment sequencing analyses. The supplied documents do not provide a comprehensive United States clinical practice or claims-based regimen library for Acute Lymphoblastic Leukemia (ALL), and they do not enumerate induction, consolidation, intensification, maintenance, or treatment-sequencing regimen groupings and aliases. The documents do identify several therapies used in relapsed or refractory ALL and transplant-related settings, including "blinatumumab," "inotuzumab," and "CAR-T cells," and they discuss "bridging therapy prior to reinjection of autologous CAR-T cells" in relapsed/refractory B-ALL. The FDA Purple Book document lists product and generic names relevant for alias grouping, including "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," and rituximab biosimilars such as "Truxima rituximab-abbs," "Ruxience rituximab-pvvr," and "Riabni rituximab-arrx." The transplant-focused guideline also states that "post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended" for Philadelphia chromosome positive ALL, but no specific multi-agent maintenance regimen compositions or sequencing rules are provided. The supplied documents identify only limited Acute Lymphoblastic Leukemia regimens and do not provide a comprehensive U.S. clinical practice or claims-based regimen library across induction, consolidation, intensification, maintenance, relapsed/refractory, and transplant-related settings through 2026-09-21. For relapsed or refractory Ph+ ALL, dasatinib (SPRYCEL) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and imatinib is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).” The documents also note a pediatric Ph+ ALL combination approach where “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy” may receive imatinib, but no specific chemotherapy backbone, induction, consolidation, maintenance, intensification, transplant-related regimen definitions, aliases, or component-grouping rules are provided. The supplied documents describe broad United States clinical practice guidance for ALL but do not provide the detailed claims-based regimen library, regimen-component grouping rules, aliases, or exhaustive multi-agent regimen names requested for sequencing analyses. The documents state that ALL management includes “risk-stratified treatment approaches,” “more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,” and that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols.” The relapsed or refractory setting is specifically referenced, with NCCN updates that “summarize treatment recommendations for R/R ALL.” Transplant-related management is also referenced, including that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do identify several treatment settings and regimen elements: relapsed/refractory management recommendations include “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” with discussion of “consolidation with allogeneic transplant” and “CNS-directed therapy.” The documents also describe “asparaginase-containing regimens” and “pediatric/pediatric-inspired regimens incorporating asparaginase” used in AYA and adult ALL populations. Maintenance therapy is described as “the last phase of treatment for acute lymphoblastic leukemia in children and adolescents,” but no specific multi-agent maintenance regimen components, aliases, or grouping conventions are supplied. The supplied documents only partially address Acute Lymphoblastic Leukemia regimens and do not provide a comprehensive United States claims-based regimen library across induction, consolidation, intensification, maintenance, relapsed/refractory, transplant-related settings, or regimen alias grouping rules. The documents identify methotrexate as being used "as part of a combination chemotherapy maintenance regimen" for ALL, clofarabine for "relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens," and imatinib mesylate for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." No induction, consolidation, intensification, transplant-conditioning regimens, sequencing logic, component grouping methodology, or regimen aliases are described in the supplied documents. The supplied documents do not provide a United States claims-based ALL regimen library, treatment-sequencing grouping rules, or comprehensive induction, consolidation, intensification, maintenance, transplant-related, or regimen-alias mappings. The only explicit relapsed/refractory regimen-related information is that nelarabine is indicated for "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)" in patients "whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens." The documents also describe a nelarabine administration schedule in relapsed/refractory T-ALL/T-LBL clinical trials: "1,500 mg/m 2 of Nelarabine Injection Administered Intravenously Over 2 Hours on Days 1, 3, and 5 Repeated Every 21 Days." No source text defines how regimen components or aliases should be grouped for sequencing analyses. The supplied documents only identify limited Acute Lymphoblastic Leukemia (ALL) treatment settings and do not provide a comprehensive U.S. claims-based regimen library through 2026-09-21. For relapsed or refractory ALL, BESPONSA (inotuzumab ozogamicin) is indicated for "relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older." For maintenance therapy, methotrexate tablets are indicated for the "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents do not describe induction regimens, consolidation regimens, intensification regimens, transplant-conditioning regimens, regimen component grouping rules, or regimen aliases/naming conventions for treatment sequencing analyses. The supplied documents identify only limited Acute Lymphoblastic Leukemia (ALL) regimen information. Methotrexate labeling states that it is used for ALL "as part of a combination chemotherapy regimen" and for "prophylaxis and treatment of meningeal leukemia," but no induction, consolidation, intensification, maintenance, transplant-related, or sequencing regimen library definitions are provided. Imatinib and dasatinib labeling identify Philadelphia chromosome-positive ALL settings, including "relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)," "newly diagnosed Ph+ ALL in combination with chemotherapy," and "Ph+ ALL with resistance or intolerance to prior therapy," but the documents do not define multi-agent regimen names, aliases, component grouping rules, or claims-based sequencing conventions. The supplied documents identify that NCCN ALL guidelines address treatment strategies and management settings for adult and pediatric acute lymphoblastic leukemia, including “risk-adapted therapy,” “frontline and relapsed/refractory management,” “hematopoietic stem cell transplantation,” and management of “BCR::ABL1-positive” and “BCR::ABL1-negative” disease. However, the documents provided do not enumerate specific multi-agent induction, consolidation, intensification, maintenance, relapsed/refractory, or transplant-related regimens, nor do they provide claims-based regimen library conventions, component grouping rules, aliases, or treatment-sequencing nomenclature. Therefore, the requested regimen lists, aliases, and grouping logic for sequencing analyses cannot be fully derived from the supplied text. The supplied documents only identify two Acute Lymphoblastic Leukemia treatment contexts and do not provide a comprehensive United States claims-based regimen library through 2026-09-21. For relapsed or refractory ALL, clofarabine is indicated "for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." For maintenance therapy, mercaptopurine is indicated "for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents do not list specific induction, consolidation, intensification, transplant-related multi-agent regimens, regimen aliases, or component-grouping rules for treatment sequencing analyses. The supplied documents do not provide a United States ALL regimen library through 2026-09-21 and do not enumerate induction, consolidation, intensification, maintenance, transplant-related, or regimen-alias grouping frameworks for treatment sequencing analyses. The documents only identify selected agents and limited usage context in ALL, including that methotrexate is used in ALL "as part of a combination chemotherapy regimen" and for "prophylaxis and treatment of meningeal leukemia." The documents also identify FDA products relevant to ALL care, including ICLUSIG (ponatinib) and ARRANON (nelarabine), but they do not describe multi-agent regimens, regimen naming conventions, or component-grouping logic. The supplied document only states that doxorubicin hydrochloride is indicated for treatment of "acute lymphoblastic leukemia" and that it may be used "in combination with other chemotherapy drugs." It does not provide United States ALL regimen libraries, induction, consolidation, intensification, maintenance, relapsed/refractory, transplant-related regimens, or guidance on regimen component grouping, aliases, or treatment sequencing analyses. Therefore, the requested regimen-level details are not available in the provided materials. The supplied documents identify the major treatment phases for Acute Lymphoblastic Leukemia (ALL), including induction chemotherapy, consolidation therapy, maintenance therapy, CNS prophylaxis, treatment of mature B-cell ALL, treatment of Philadelphia chromosome–positive ALL, and treatment of younger adults, but they do not provide a complete claims-oriented regimen library or detailed multi-agent regimen component mappings and aliases for sequencing analyses. The documents also do not enumerate specific regimen names, standardized aliases, component-grouping rules, transplant-conditioning regimens, or relapsed/refractory regimen taxonomies. Therefore, the available material only partially addresses the requested scope.

CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiBulletin du cancerFDA Purple BookUS Food and Drug AdministrationJournal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican journal of hematologyDr.Reddy's Laboratories IncAlembic Pharmaceuticals Inc.Sun Pharmaceutical Industries, Inc.Alembic Pharmaceuticals LimitedNational Library of Medicine (DailyMed)Aurobindo Pharma LimitedBryant Ranch PrepackHospira, Inc.Apotex CorpBluePoint LaboratoriesAmneal Pharmaceuticals LLCHikma Pharmaceuticals USA Inc.Pfizer Laboratories Div Pfizer IncOpen web

What HCPCS J-codes and NDC identifiers map to ALL regimen components?

The supplied documents identify several Acute Lymphoblastic Leukemia regimen component drugs and branded products, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic mappings. Clofarabine injection is described as "indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." Imatinib mesylate is described for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The Drugs@FDA record identifies the branded product SPRYCEL with multiple tablet strengths, but no claims-code mappings or administration linkages are provided. The supplied documents provide HCPCS/J-code mappings for several Acute Lymphoblastic Leukemia regimen component drugs used in treatment sequencing analyses, including rituximab (J9312), blinatumomab (J9039), inotuzumab ozogamicin (J9229), vincristine sulfate (J9370), doxorubicin hydrochloride (J9000), cyclophosphamide (J9070), methotrexate sodium (J9250 and J9260), cytarabine (J9100), daunorubicin hydrochloride (J9150), tisagenlecleucel (Q2042), and brexucabtagene autoleucel (Q2053). The documents also specifically confirm that HCPCS code J9039 corresponds to “Injection, blinatumomab, 1 microgram” and HCPCS code J9229 corresponds to “Injection, inotuzumab ozogamicin, 0.1 mg.” However, the supplied documents do not provide NDC mappings, biosimilar mappings, multi-source generic mappings beyond the named generic ingredients, or CPT drug-administration code linkage. The documents identify imatinib mesylate tablets for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." They also identify clofarabine injection "for intravenous use" for pediatric relapsed/refractory ALL and methotrexate injection "for intravenous, intramuscular, subcutaneous, or intrathecal use" for ALL as part of combination chemotherapy regimens. The supplied documents identify regimen component drugs used in Acute Lymphoblastic Leukemia (ALL) treatment contexts, specifically methotrexate and clofarabine, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic mapping tables. Methotrexate labeling states it is indicated for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." Clofarabine labeling states it is indicated for "pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." No claims-code linkage or administration-code mapping information is present in the documents. The supplied documents identify several Acute Lymphoblastic Leukemia regimen component products and some HCPCS mappings, including branded products and rituximab biosimilars. The FDA Purple Book rows list "Rituxan rituximab," "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," and biosimilars "Truxima rituximab-abbs (biosimilar to Rituxan)," "Ruxience rituximab-pvvr (biosimilar to Rituxan)," and "Riabni rituximab-arrx (biosimilar to Rituxan)." The HCPCS tables map tisagenlecleucel to HCPCS codes Q2040 and Q2042 with detailed code descriptions. The documents do not provide NDC mappings, J-codes, CPT drug-administration codes, or multi-source generic mappings. The documents state that SPRYCEL (dasatinib) is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.” They also identify branded products relevant to leukemia treatment sequencing analyses, including “ICLUSIG TABLET ORAL” in multiple strengths and “ARRANON INJECTABLE INTRAVENOUS strength 250MG/50ML (5MG/ML).” No administration code linkage or claims-code crosswalks are provided in the supplied material. The supplied documents identify several regimen component drugs and treatment contexts for Acute Lymphoblastic Leukemia (ALL), including BESPONSA (inotuzumab ozogamicin), BLINCYTO (blinatumomab), KYMRIAH (tisagenlecleucel), and comparator chemotherapy regimens containing fludarabine, cytarabine, mitoxantrone, granulocyte colony-stimulating factor, and high-dose cytarabine. However, the documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multisource generic mappings. The documents also describe administration modality for BLINCYTO and KYMRIAH, including intravenous infusion and continuous IV infusion schedules, but no billing-code linkage is provided. The supplied documents identify regimen component drugs used for Acute Lymphoblastic Leukemia treatment analyses, including doxorubicin hydrochloride and methotrexate sodium formulations, and include branded and multi-source generic injectable product descriptions. However, the documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, or NDC mappings. The documents do provide evidence that doxorubicin hydrochloride is indicated for “acute lymphoblastic leukemia” and list multiple methotrexate injectable product variants and preservative-free formulations that could correspond to generic product mapping exercises in claims-based sequencing analyses. The supplied documents provide limited NDC mapping information for dasatinib products relevant to Acute Lymphoblastic Leukemia treatment sequencing analyses. Documented products include Biocon Pharma Inc. ANDA dasatinib tablet products with NDC package identifiers "70377-087-11" and "70377-088-11" for 100 mg and 140 mg strengths, respectively, and a Prasco Laboratories "NDA AUTHORIZED GENERIC" dasatinib 20 mg tablet product with package identifier "66993-233-60." The documents identify these as generic or authorized generic oral products, but they do not provide HCPCS codes, J-codes, CPT drug-administration linkage, biosimilar mappings, or broader multi-source generic mappings. The supplied documents provide limited HCPCS/J-code mappings for several Acute Lymphoblastic Leukemia treatment components. Documented mappings include HCPCS code C9449 for blinatumomab defined as "Injection, blinatumomab, 1 mcg," HCPCS code C9028 for inotuzumab ozogamicin defined as "Injection, inotuzumab ozogamicin, 0.1 mg," and HCPCS code Q2053 for brexucabtagene autoleucel defined as "up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." The documents do not provide NDC mappings, biosimilar mappings, multi-source generic mappings, or CPT drug-administration code linkages. The supplied documents identify doxorubicin (Adriamycin/DOXOrubicin HCl) as a regimen component drug used for treatment of acute lymphoblastic leukemia and describe intravenous administration details, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic coding crosswalks. The labels state that "Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia" and describe administration "as an intravenous injection" and dosing in "combination with other chemotherapy drugs." No claims-data coding mappings or administration billing code linkages are present in the documents. The documents do establish branded/generic drug identities and ALL-related treatment use cases: nelarabine injection for relapsed or refractory T-ALL/T-LBL, dasatinib tablets for Ph+ ALL, and mercaptopurine oral suspension for ALL maintenance therapy. No administration-code linkage or claims-code crosswalks are present in the supplied materials. The supplied documents provide limited NDC mappings for branded oral ALL therapies, specifically SPRYCEL (dasatinib) and Iclusig (ponatinib hydrochloride). Document 0 identifies SPRYCEL with package NDC "0003-0524-11" and active ingredient "DASATINIB 70 mg/1," while Document 1 identifies SPRYCEL with package NDC "0003-0857-22" and active ingredient "DASATINIB 140 mg/1." Document 2 identifies Iclusig with package NDC "63020-533-30" and active ingredient "PONATINIB HYDROCHLORIDE 30 mg/1." The documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, generic product mappings, or treatment sequencing linkage information. The documents provide limited NDC mappings for several Acute Lymphoblastic Leukemia regimen component drugs, including branded and generic products, but they do not provide HCPCS, J-code, CPT drug-administration, biosimilar linkage, or treatment sequencing analysis mappings. Documented NDC products include Clofarabine injection marketed as an ANDA generic with package code 43598-309-20, Arranon (nelarabine) intravenous injection with package code 66758-165-94, and Dasatinib oral tablets with package code 70377-085-11. The supplied records identify product names, active ingredients, dosage forms, package identifiers, and marketing categories only. The supplied documents provide limited mappings for regimen component drugs relevant to Acute Lymphoblastic Leukemia claims analyses. HCPCS mapping is available for imatinib: HCPCS code S0088 is defined as “Imatinib 100 mg — Imatinib, 100 mg.” NDC mappings are provided for branded and generic kinase inhibitors, including IMKELDI (imatinib oral solution) with NDC 81927-201-01 and an authorized generic dasatinib product with NDC 66993-234-60. The documents do not provide CPT drug-administration code linkage, biosimilar mappings, or broader multisource generic mapping tables beyond the specific examples shown. The supplied documents provide limited mappings relevant to Acute Lymphoblastic Leukemia treatment sequencing analyses. HCPCS mappings are provided for obecabtagene autoleucel under codes C9301 and Q2058, including descriptions of the leukapheresis and infusion-related therapeutic dose definitions. An NDC mapping is provided for Arranon (nelarabine) intravenous injection under NDC 0078-0683-61 with active ingredient nelarabine 5 mg/mL. The documents do not provide broader HCPCS/J-code mappings, CPT drug-administration linkage, biosimilar mappings, or multi-source generic mappings beyond these examples. The supplied documents only provide partial NDC mapping information for dasatinib generic products and do not provide HCPCS, J-code, CPT drug-administration, biosimilar, or treatment-sequencing linkage information. The documents identify Biocon Pharma Inc. oral dasatinib tablet products with NDC package identifiers 70377-083-11 (20 mg), 70377-084-11 (50 mg), and 70377-086-11 (80 mg), each with marketing category "ANDA," indicating generic products. No branded-product mappings, biosimilar mappings, HCPCS/J-codes, or administration code linkages are present in the supplied material. The documents provide NDC mappings for the branded product Iclusig (ponatinib hydrochloride), including multiple strengths and package configurations. Specifically, NDC 63020-534 corresponds to 45 mg tablets, NDC 63020-536 corresponds to 10 mg tablets, and NDC 63020-535 corresponds to 15 mg tablets with both 30-count and 60-count bottle presentations. The supplied documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, or multi-source generic mappings for treatment sequencing analyses. A HCPCS mapping is provided for brexucabtagene autoleucel under code C9073, and NDC mappings are provided for branded SPRYCEL (dasatinib) oral tablets with NDC package identifiers 0003-0855-22 and 0003-0528-11. The documents do not provide CPT drug-administration linkage, biosimilar mappings, multi-source generic mappings, or broader treatment sequencing mappings through 2026-09-21.

Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBBCMS HCPCS Release FilesU.S. National Library of MedicineApotex CorpAmneal Pharmaceuticals LLCHospira, Inc.Aurobindo Pharma LimitedBryant Ranch PrepackFDA Purple BookTAKEDA PHARMS USASANDOZNational Library of Medicine (DailyMed)HOSPIRAPfizer Laboratories Div Pfizer IncBiocon Pharma Inc.Prasco LaboratoriesAlembic Pharmaceuticals LimitedBluePoint LaboratoriesHikma Pharmaceuticals USA Inc.E.R. Squibb & Sons, L.L.C.Takeda Pharmaceuticals America, Inc.Sandoz IncShorla Oncology Inc.,Novartis Pharmaceuticals Corporation

Which ALL therapies are billed under the pharmacy benefit versus the medical benefit?

The documents identify oral and intravenous ALL therapies, but they do not discuss United States claims adjudication under pharmacy versus medical benefit, dual-channel billing, or line-of-therapy routing ambiguities. SPRYCEL (dasatinib) for Philadelphia chromosome-positive acute lymphoblastic leukemia is described as an oral tablet therapy: "SPRYCEL TABLET ORAL" and "The recommended starting dosage of SPRYCEL for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL is 140 mg administered orally once daily." KYMRIAH (tisagenlecleucel) for relapsed or refractory B-cell ALL is described as "suspension for intravenous infusion" and as a "CD19-directed genetically modified autologous T cell immunotherapy." The supplied documents do not state whether these products are adjudicated through pharmacy or medical benefits, nor do they describe benefit-routing ambiguities or dual-channel billing patterns affecting line-of-therapy construction. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and specify that they are administered intravenously, but they do not explicitly describe adjudication under pharmacy versus medical benefits, dual-channel billing, or claims-routing ambiguities. BLINCYTO (blinatumomab) is described as “for injection, for intravenous use,” and is indicated for multiple ALL settings including “relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).” Doxorubicin hydrochloride is also described as “injection, for intravenous use” and is indicated for “acute lymphoblastic leukemia,” including use “as a component of multi-agent adjuvant chemotherapy.” The documents do not provide information on oral therapies, pharmacy-benefit dispensing, medical-benefit adjudication practices, or how benefit-routing ambiguities affect line-of-therapy construction in U.S. claims data. The documents identify oral maintenance-regimen therapies for Acute Lymphoblastic Leukemia (ALL), specifically mercaptopurine oral suspension and methotrexate tablets, which implies pharmacy-dispensed oral agents rather than infused medical-benefit products. Mercaptopurine is described as "MERCAPTOPURINE oral suspension" with dosing "orally once daily as part of a combination chemotherapy maintenance regimen." Methotrexate is described as "METHOTREXATE tablets, for oral use" and is indicated for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The supplied documents do not discuss United States claims adjudication, pharmacy versus medical benefit routing rules, dual-channel billing, infused agents, or line-of-therapy construction ambiguities, so those aspects cannot be determined from the provided evidence. The supplied documents identify multiple Acute Lymphoblastic Leukemia therapies and regimen components through HCPCS injection or CAR-T procedure codes, which indicates adjudication in claims systems tied to HCPCS-coded administration. Documented HCPCS-coded agents include rituximab, blinatumomab, inotuzumab ozogamicin, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, tisagenlecleucel, and brexucabtagene autoleucel. The documents also show CAR-T products billed with HCPCS Q-codes that include administration-related language such as “including leukapheresis and dose preparation procedures, per infusion” and “per therapeutic dose.” The documents do not describe pharmacy-benefit therapies, oral agents, dual-channel billing, or routing ambiguities affecting line-of-therapy construction. The documents identify several Acute Lymphoblastic Leukemia therapies and products that appear in HCPCS and FDA product listings, including blinatumomab (Blincyto), inotuzumab ozogamicin (Besponsa), tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), and obecabtagene autoleucel (Aucatzyl). The HCPCS entries for obecabtagene autoleucel describe administration-linked billing constructs such as “including leukapheresis and dose preparation procedures” and billing “per therapeutic dose” or “per infusion,” which indicates medical-claim routing through HCPCS-coded services. However, the supplied documents do not state which therapies are adjudicated under the pharmacy benefit versus the medical benefit, do not describe oral versus infused benefit routing, and do not discuss dual-channel billing patterns or line-of-therapy construction ambiguities. The supplied documents identify some Acute Lymphoblastic Leukemia therapies as oral tablet products, including imatinib mesylate and ponatinib (ICLUSIG). Imatinib mesylate is described as “tablets, for oral use” and includes indications for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” ICLUSIG is identified as “TABLET ORAL” in multiple strengths. However, the documents do not discuss United States claims adjudication under pharmacy versus medical benefits, do not describe infused versus medically billed agents, and do not address dual-channel billing patterns, routing ambiguities, or line-of-therapy construction issues. The documents identify several Acute Lymphoblastic Leukemia (ALL) therapies as oral tablet products, which in claims practice could correspond to pharmacy-dispensed agents, but the documents do not explicitly discuss pharmacy versus medical benefit adjudication. The ALL-related oral agents named are methotrexate tablets, imatinib mesylate tablets, and dasatinib tablets. The documents also reference use "in combination with chemotherapy" or as part of a "combination chemotherapy maintenance regimen," indicating that oral agents may be combined with other chemotherapy components, but they do not specify whether those accompanying chemotherapy agents are infused, medically billed, dual-channeled, or associated with routing ambiguities affecting line-of-therapy construction. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and regimen components, but they do not describe United States claims adjudication under pharmacy versus medical benefits or line-of-therapy routing logic. The documents do show that Methotrexate for ALL is provided as an injectable therapy and may involve intramuscular, subcutaneous, intravenous, or intrathecal administration, while also noting that patients may switch between oral and injectable methotrexate formulations. The documents also describe TECARTUS (brexucabtagene autoleucel) as a "single dose" CAR-T cell therapy. No document discusses dual-channel billing, pharmacy-benefit claims, medical-benefit claims, or benefit-routing ambiguities affecting line-of-therapy construction. The documents identify both oral and intravenous ALL therapies, which are relevant to potential pharmacy-versus-medical benefit routing, but they do not directly describe United States claims adjudication practices, dual-channel billing, or line-of-therapy construction rules. IMKELDI is described as an "SOLUTION ORAL," while nelarabine/Arranon are described as "injection" products for "intravenous use," including dosing administered "intravenously over" specified time periods. The supplied documents do not state whether these products are typically processed under pharmacy or medical benefits, and they do not discuss routing ambiguities or dual-channel billing patterns. The supplied documents identify several Acute Lymphoblastic Leukemia therapies as intravenous injectable products, which implies administration in a clinical setting but does not explicitly discuss United States claims adjudication under pharmacy versus medical benefits. Clofarabine is repeatedly described as an "injection" administered "as an intravenous infusion," and ARRANON is listed as an "INJECTABLE INTRAVENOUS" product. The documents do not provide information about pharmacy-benefit therapies, dual-channel billing, oral-versus-infused routing distinctions in claims systems, or benefit-routing ambiguities affecting line-of-therapy construction. The documents identify several Acute Lymphoblastic Leukemia therapies and their coding or dosage-form characteristics, but they do not directly state whether they are adjudicated under the pharmacy benefit or medical benefit in U.S. claims data, nor do they describe line-of-therapy routing ambiguities. Imatinib appears in HCPCS coding as "HCPCS code S0088," while ponatinib (Iclusig) is described as an oral "TABLET, FILM COATED ORAL" product in FDA NDC records. The supplied documents do not discuss dual-channel billing patterns, infused versus physician-administered adjudication, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied document identifies therapies and regimen components used in Acute Lymphoblastic Leukemia treatment studies, including “BESPONSA,” “fludarabine + cytarabine + granulocyte colony-stimulating factor flag,” “mitoxantrone + cytarabine mxn/ara-c,” and “high dose cytarabine hidac.” The document also describes that patients received “treatment cycles” and compares “BESPONSA” with “Investigator’s choice of chemotherapy.” However, the document does not discuss United States claims adjudication, pharmacy versus medical benefit routing, oral versus infused benefit handling, dual-channel billing, or line-of-therapy construction ambiguities. The supplied documents identify Acute Lymphoblastic Leukemia therapies that are administered as intravenous injections or infusions, including clofarabine and nelarabine. Clofarabine is described as an “INJECTION INTRAVENOUS” product and its labeling states it is administered “as an intravenous infusion over 2 hours daily for 5 consecutive days.” Nelarabine (Arranon) is also described as an “INJECTION INTRAVENOUS” product. The documents do not provide information about adjudication under pharmacy versus medical benefits, dual-channel billing, oral versus infused benefit routing distinctions, or claims-based line-of-therapy ambiguities. The supplied documents identify doxorubicin as a therapy used for "acute lymphoblastic leukemia" and repeatedly describe it as being administered intravenously, including "given intravenously every 21 days," "administered as an intravenous bolus," and "Administration by Intravenous Injection." These documents therefore support that doxorubicin is an infused or injected regimen component rather than an oral agent. The documents identify several Acute Lymphoblastic Leukemia therapies through HCPCS billing codes that are associated with administered products typically appearing in medical claims. HCPCS code C9073 and HCPCS code Q2053 are both defined for "Brexucabtagene autoleucel" and include "leukapheresis and dose preparation procedures, per therapeutic dose," while HCPCS code J9039 is defined as "Injection, blinatumomab, 1 microgram." The supplied documents do not describe pharmacy-benefit adjudication, oral therapies, dual-channel billing, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied documents identify dasatinib products as oral tablet formulations, including "Product: Dasatinib (dasatinib) TABLET ORAL" and "Product: SPRYCEL (dasatinib) TABLET ORAL." However, the documents do not state whether these therapies are adjudicated under the pharmacy benefit or the medical benefit, and they do not describe dual-channel billing, infused agents, regimen-component routing, or line-of-therapy construction ambiguities. No information is provided about medical-benefit therapies, oral-versus-infused adjudication rules, or benefit-routing patterns in claims data. The documents identify certain Acute Lymphoblastic Leukemia therapies as HCPCS-coded injectable products, which are typically represented in medical claims data. Specifically, HCPCS code J9229 is defined as "Injection, inotuzumab ozogamicin, 0.1 mg," HCPCS code C9028 is also defined as "Injection, inotuzumab ozogamicin, 0.1 mg," and HCPCS code C9449 is defined as "Injection, blinatumomab, 1 mcg." The supplied documents do not discuss pharmacy-benefit adjudication, oral therapies, dual-channel billing, benefit-routing ambiguities, or impacts on line-of-therapy construction. The supplied documents identify dasatinib products as oral tablet therapies, which implies they are dispensed products rather than infused agents. The records state "Product: SPRYCEL (dasatinib) TABLET ORAL" and "Product: Dasatinib (dasatinib) TABLET, FILM COATED ORAL." However, the documents do not discuss United States claims adjudication under pharmacy versus medical benefits, do not identify medical-benefit therapies, and do not describe dual-channel billing patterns, routing ambiguities, or impacts on line-of-therapy construction. The supplied documents identify oral ALL-related therapies that would typically appear as pharmacy-dispensed products because they are described as oral tablets or oral solution products with NDC packaging. Ponatinib (Iclusig) is listed as a "TABLET, FILM COATED ORAL" product in bottle packaging, and imatinib (IMKELDI) is listed as a "SOLUTION ORAL" product. The documents do not describe any infused therapies, medical-benefit adjudication, dual-channel billing, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied documents identify dasatinib/SPRYCEL as an oral tablet product, which is relevant to pharmacy-versus-medical benefit routing because the products are described as "TABLET ORAL." Specifically, the documents describe both branded SPRYCEL and generic dasatinib oral tablet formulations. However, the documents do not describe United States claims adjudication practices, pharmacy benefit versus medical benefit assignment, dual-channel billing, infused therapies, regimen components, or line-of-therapy routing ambiguities. The supplied documents identify dasatinib formulations that are "TABLET, FILM COATED ORAL," which indicates an oral therapy form relevant to Acute Lymphoblastic Leukemia treatment claims. However, the documents do not describe whether therapies are adjudicated under the pharmacy benefit or medical benefit, do not discuss infused agents, and do not provide information on dual-channel billing patterns, routing ambiguities, or line-of-therapy construction rules in United States claims data.

US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer IncHikma Pharmaceuticals USA Inc.Alembic Pharmaceuticals Inc.Aurobindo Pharma LimitedCMS HCPCS Release FilesU.S. National Library of MedicineFDA Purple BookSun Pharmaceutical Industries, Inc.TAKEDA PHARMS USABryant Ranch PrepackApotex CorpBluePoint LaboratoriesHospira, Inc.SHORLA ONCOLOGYAlembic Pharmaceuticals LimitedNovartis Pharmaceuticals CorporationDr.Reddy's Laboratories IncSANDOZTakeda Pharmaceuticals America, Inc.Sandoz IncAmneal Pharmaceuticals LLCPrasco LaboratoriesE.R. Squibb & Sons, L.L.C.Biocon Pharma Inc.Shorla Oncology Inc.,

What supportive care agents should be excluded from ALL regimen identification?

The supplied documents identify some supportive or prophylactic agents associated with acute lymphoblastic leukemia care, but they do not provide a comprehensive exclusion list for regimen identification or line-of-therapy assignment in United States claims analyses. The documents mention prophylactic anticoagulation and supportive growth-factor use: in ALL, "Low-molecular-weight heparins (LMWH) at prophylactic doses are recommended as the first-line strategy" and "Direct oral anticoagulants (DOACs) may be considered" in selected situations; in leukemia supportive care, LEUKINE is described as "a leukocyte growth factor indicated" "To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections." The documents also reference transfusion support through measures such as "platelet (>20,000 cells/mm3) and RBC transfusion independence." No supplied document addresses anti-infective prophylaxis agents, antiemetics, rescue agents, tumor lysis management drugs, or explicit non-therapeutic exclusions for claims-based regimen construction. The supplied documents mention supportive care in acute lymphoblastic leukemia guidelines, but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor lysis, antiemetic, anti-infective, growth factor, or non-therapeutic agents that should be excluded from regimen identification or line-of-therapy assignment in United States claims analyses. One document states that the NCCN guidelines include “guidance on supportive care,” and another refers to “enhanced supportive care,” but neither provides the requested exclusion lists or agent names. The supplied document indicates that ALL guidelines include “supportive care considerations,” but it does not specify which supportive-care, prophylactic, rescue, adjunctive, or non-therapeutic agents should be excluded from regimen identification or line-of-therapy assignment in United States claims analyses. The document also does not provide lists covering anti-infective prophylaxis, growth factor support, antiemetics, tumor lysis management, transfusion support, or non-therapeutic exclusions. The supplied documents indicate that NCCN Acute Lymphoblastic Leukemia guidelines include “supportive care considerations,” but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor-lysis, antiemetic, growth-factor, anti-infective, or non-therapeutic agents to exclude from regimen identification or line-of-therapy assignment in claims analyses. No document provides a list of medications or coding exclusions for treatment sequencing analyses.

US Food and Drug AdministrationBulletin du cancerJournal of the National Comprehensive Cancer Network : JNCCN

What NDC identifiers and labelers correspond to the principal ALL agents, and where are biosimilars or multi-source generics involved?

The supplied documents identify methotrexate-containing therapies used in Acute Lymphoblastic Leukemia (ALL), including oral tablets, injectable products, and an oral solution, but they do not provide representative NDC identifiers, biosimilar relationships, or a complete exhaustive pull methodology. The Bryant Ranch Prepack labeling states that “Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” while the Hospira Drugs@FDA entry enumerates multiple injectable package presentations and strengths such as “METHOTREXATE SODIUM PRESERVATIVE FREE INJECTABLE INJECTION strength EQ 1GM BASE/40ML (EQ 25MG BASE/ML)” and “METHOTREXATE SODIUM INJECTABLE INJECTION strength EQ 50MG BASE/2ML (EQ 25MG BASE/ML).” Manufacturer or sponsor mapping is partially available because the sources are identified as “HOSPIRA,” “Bryant Ranch Prepack,” and “SHORLA ONCOLOGY,” and the IMKELDI entry states “Application: NDA219097 sponsored by SHORLA ONCOLOGY.” The documents also support multi-source generic considerations for methotrexate because multiple formulations and manufacturers are represented, including discontinued and prescription injectable products under the same active ingredient. The supplied documents identify some principal Acute Lymphoblastic Leukemia (ALL) therapies and classes used in treatment recommendations, but they do not provide the requested exhaustive United States claims-based drug identification universe elements such as NDC identifiers, manufacturer/labeler mappings, package presentations, biosimilar relationships, or multi-source generic logic. The NCCN guideline states that the ALL guidelines focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL,” while another document states that “Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.” One FDA labeling document states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.” However, none of the supplied documents contain representative NDCs, package presentations, manufacturer or labeler mappings, biosimilar relationships, or exhaustive pull methodologies for claims data extraction. The documents identify several principal Acute Lymphoblastic Leukemia (ALL) therapies and provide limited NDC, manufacturer/labeler, package, and coding details. The only explicit NDC/package/manufacturer mapping provided is for IMKELDI: "NDC 81927-201: IMKELDI" from "Shorla Oncology Inc." with packaging "140 mL in 1 BOTTLE (81927-201-01)" and active ingredient "IMATINIB MESYLATE 80 mg/mL." BLINCYTO is identified as "BLINCYTO (BLINATUMOMAB) KIT [AMGEN, INC]" and described as indicated for "B-cell precursor acute lymphoblastic leukemia (ALL)." CMS HCPCS release data additionally identify claims-relevant agents including blinatumomab, inotuzumab ozogamicin, rituximab, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, tisagenlecleucel, and brexucabtagene autoleucel, but the supplied documents do not provide exhaustive NDC universes, biosimilar relationships, or multi-source generic mappings through 2026-09-21. The documents identify dasatinib/SPRYCEL as a principal Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) therapy and provide manufacturer or labeler names plus dosage-form strengths, but they do not provide explicit NDC identifiers, package presentations, biosimilar relationships, or exhaustive multi-source generic pull methodology. The branded product is "SPRYCEL" sponsored by "BRISTOL MYERS SQUIBB," with oral tablet strengths of "20MG," "50MG," "70MG," "80MG," "100MG," and "140MG." Generic labeling is also documented for "Dasatinib tablets" from "BluePoint Laboratories" and "Biocon Pharma Limited," and another SPRYCEL label references "Physicians Total Care, Inc." The supplied records support inclusion of branded and generic dasatinib products in a claims-based drug universe for Ph+ ALL, but the documents do not contain the exhaustive NDC-level inventory, package configurations, biosimilar mappings, or generic sourcing rules requested. The supplied documents identify representative NDCs, labelers/manufacturers, package presentations, and marketing categories for selected Acute Lymphoblastic Leukemia therapies, specifically Iclusig (ponatinib hydrochloride) and generic dasatinib products from Biocon Pharma Inc. Takeda Pharmaceuticals America, Inc. markets Iclusig under NDC 63020-535 with bottle presentations containing 30 or 60 film-coated tablets, while Biocon Pharma Inc. markets dasatinib ANDA products under NDCs 70377-083 and 70377-085 with 60-tablet bottle presentations at 20 mg and 70 mg strengths respectively. The documents support that dasatinib products are marketed under ANDA, which is relevant to multi-source generic considerations, whereas Iclusig is marketed under NDA. The documents do not provide biosimilar relationships, a complete ALL therapy universe, exhaustive pull methodology, or broader manufacturer-labeler mappings beyond the cited products. The supplied documents identify several Acute Lymphoblastic Leukemia-related therapies and their manufacturers or labelers, but they do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The documents identify “KYMRIAH (TISAGENLECLEUCEL) INJECTION, SUSPENSION novartis pharmaceuticals corporation”, “TECARTUS (BREXUCABTAGENE AUTOLEUCEL) SUSPENSION [KITE PHARMA, INC.]”, and “NELARABINE (NELARABINE)” from “Alembic Pharmaceuticals Limited”. The Nelarabine labeling specifically states that “Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)”. No supplied document contains representative NDCs, manufacturer-labeler crosswalks beyond the label names, package configurations, biosimilar mappings, or generic universe construction rules. The supplied documents identify imatinib mesylate as a therapy used for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The documents also identify multiple labelers or sources for the same product labeling, including "Apotex Corp," "Sun Pharmaceutical Industries, Inc.," and "US Food and Drug Administration (FDA Drug Labeling (openFDA), tier 1)." However, the documents do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology for claims-based drug identification universes through 2026-09-21. The supplied documents identify several principal Acute Lymphoblastic Leukemia therapies and certain biosimilar relationships from the FDA Purple Book, including Rituxan/rituximab, Blincyto/blinatumomab, Besponsa/inotuzumab ozogamicin, Kymriah/tisagenlecleucel, Tecartus/brexucabtagene autoleucel, Aucatzyl/obecabtagene autoleucel, and the rituximab biosimilars Truxima, Ruxience, and Riabni. The documents also provide representative NDC identifiers, package presentations, and manufacturer/labeler information for authorized generic dasatinib products from Prasco Laboratories, specifically NDCs 66993-233-60 and 66993-234-60. However, the documents do not provide an exhaustive ALL claims-identification universe through 2026-09-21, do not enumerate all manufacturers/labelers or package configurations for the listed therapies, and do not describe a complete pull methodology. The supplied documents identify representative Acute Lymphoblastic Leukemia therapy products and their NDC/package/manufacturer mappings, including Iclusig (ponatinib hydrochloride), Arranon (nelarabine), and SPRYCEL (dasatinib). lists Iclusig under NDC 63020-536 with package presentation "30 TABLET, FILM COATED in 1 BOTTLE (63020-536-30)"; Novartis Pharmaceuticals Corporation lists Arranon under NDC 0078-0683 with package presentation "50 mL in 1 VIAL (0078-0683-61)"; and E.R. Squibb & Sons, L.L.C. lists SPRYCEL under NDC 0003-0855 with package presentation "1 BOTTLE in 1 CARTON (0003-0855-22) / 30 TABLET in 1 BOTTLE." The documents do not provide biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology, and they do not establish a complete ALL therapy universe through 2026-09-21. The documents identify two Acute Lymphoblastic Leukemia therapies and their sponsors/labelers, but they do not provide representative NDC identifiers, package presentations, biosimilar relationships, or exhaustive multi-source generic pull methodology. ICLUSIG is identified under "NDA203469 sponsored by TAKEDA PHARMS USA" with oral tablet products at strengths "EQ 10MG BASE," "EQ 45MG BASE," "EQ 30MG BASE," and "EQ 15MG BASE." Methotrexate Injection is identified from Hospira, Inc. labeling as indicated for "acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen" and described as "for intravenous, intramuscular, subcutaneous, or intrathecal use." The supplied documents do not state any NDC numbers, package sizes, biosimilar relationships, interchangeable products, or generic universe methodology. The supplied documents identify Biocon Pharma Inc. as the labeler/manufacturer source for several dasatinib oral tablet NDCs relevant to Acute Lymphoblastic Leukemia claims identification. Representative NDCs include 70377-084-11 for 50 mg tablets packaged as "60 TABLET, FILM COATED in 1 BOTTLE," 70377-086-11 for 80 mg tablets packaged as "30 TABLET, FILM COATED in 1 BOTTLE," and 70377-087-11 for 100 mg tablets packaged as "30 TABLET, FILM COATED in 1 BOTTLE." All listed products are marketed under the "ANDA" category, which indicates generic approval status in the FDA NDC Directory entries. The documents do not provide exhaustive ALL therapy coverage, biosimilar relationships, broader manufacturer mappings, or a complete pull methodology for claims-universe construction. The supplied documents identify Acute Lymphoblastic Leukemia (ALL) therapies including methotrexate and imatinib, but they do not provide an exhaustive U.S. claims-data drug identification universe through 2026-09-21. The documents show that methotrexate tablets from multiple manufacturers are indicated for “acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” demonstrating a multi-source generic situation across at least Alembic Pharmaceuticals and Aurobindo Pharma. The HCPCS material also identifies imatinib under HCPCS code S0088 as “Imatinib 100 mg — Imatinib, 100 mg.” However, the documents do not provide representative NDC identifiers, package presentations, biosimilar relationships, or exhaustive pull methodology. The supplied documents identify representative NDCs for ALL-related kinase inhibitor therapies including Dasatinib and Iclusig/Ponatinib products. Biocon Pharma Inc. markets an ANDA dasatinib product under NDC 70377-088 with package presentation "30 TABLET, FILM COATED in 1 BOTTLE (70377-088-11)" and active ingredient strength "DASATINIB 140 mg/1." Takeda Pharmaceuticals America, Inc. markets Iclusig (ponatinib hydrochloride) NDA products under NDCs 63020-533 and 63020-534, each packaged as "30 TABLET, FILM COATED in 1 BOTTLE" with strengths "30 mg/1" and "45 mg/1" respectively. The documents do not provide biosimilar relationships, broader multi-source generic considerations, or an exhaustive pull methodology for claims-based drug identification universes. The supplied documents identify doxorubicin products used for Acute Lymphoblastic Leukemia treatment indications, including branded and generic presentations such as “Doxorubicin Hydrochloride Injection,” “Adriamycin (DOXOrubicin HCl) for Injection, USP,” and “Adriamycin (DOXOrubicin HCl) Injection, USP.” The documents also provide limited package presentation details through vial strengths and reconstitution instructions, including “10 mg doxorubicin HCl vial” and “50 mg doxorubicin HCl vial.” However, the documents do not provide NDC identifiers, manufacturer-labeler crosswalks beyond Pfizer and FDA SPL references, biosimilar relationships, multi-source generic methodology, or exhaustive claims pull methodology for ALL therapies through 2026-09-21. The supplied documents identify clofarabine injection as an Acute Lymphoblastic Leukemia therapy and show multiple manufacturers/labelers associated with the product, including Amneal Pharmaceuticals, Ingenus Pharmaceuticals, LLC, and Dr. Reddy’s Laboratories Inc. The documents consistently state that clofarabine injection is indicated "for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." However, the documents do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology for United States claims data through 2026-09-21. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and limited coding/manufacturer information, but they do not provide an exhaustive U.S. claims-based drug identification universe through 2026-09-21. The documents identify blinatumomab through HCPCS code C9449, ARRANON (nelarabine) with sponsor/manufacturer SANDOZ and injectable presentation strength, and mercaptopurine oral suspension indicated for ALL maintenance therapy. However, the documents do not provide representative NDC identifiers, complete manufacturer or labeler mappings, package presentations across products, biosimilar relationships, multi-source generic mappings, or an exhaustive pull methodology. The supplied documents identify HCPCS-coded ALL cellular therapies relevant to claims identification, specifically tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel. The documents provide HCPCS identifiers and therapy descriptions including therapeutic-dose definitions and leukapheresis/dose preparation inclusion, but they do not provide NDC identifiers, manufacturers or labelers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The available claims-identification details are HCPCS Q2042 for tisagenlecleucel, HCPCS C9073 for brexucabtagene autoleucel, and HCPCS C9301 for obecabtagene autoleucel. The supplied documents provide only a limited subset of an Acute Lymphoblastic Leukemia (ALL) drug-identification universe. They identify a generic clofarabine injection from Dr. Reddy’s Laboratories with NDC 43598-309-20 and an NDA nelarabine product (Arranon) from Sandoz with NDC 66758-165-94, including package presentations and marketing categories. The documents also identify BESPONSA (inotuzumab ozogamicin) as indicated for relapsed or refractory CD22-positive B-cell precursor ALL, but they do not provide NDCs, package configurations, biosimilar relationships, exhaustive manufacturer mappings, or a comprehensive pull methodology for all principal ALL therapies through 2026-09-21. The supplied documents identify representative NDCs for SPRYCEL (dasatinib) oral tablets from E.R. Squibb & Sons, L.L.C., including NDCs 0003-0528, 0003-0524, and 0003-0857. Package presentations include 60-tablet bottles and 30-tablet bottles packaged as "1 BOTTLE in 1 CARTON," with strengths of 50 mg, 70 mg, and 140 mg respectively. All listed products have marketing category "NDA" and marketing start dates ranging from 2006-06-27 to 2010-10-28. The documents do not provide biosimilar relationships, multi-source generic considerations, broader ALL therapy coverage, or an exhaustive pull methodology for claims-based drug identification through 2026-09-21. The supplied documents identify HCPCS-coded Acute Lymphoblastic Leukemia therapies but do not provide NDC identifiers, manufacturer or labeler mappings, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The documents identify HCPCS code J9229 for inotuzumab ozogamicin, HCPCS code Q2040 for tisagenlecleucel, and HCPCS code Q2053 for brexucabtagene autoleucel. Because the documents are limited to HCPCS descriptions, the requested exhaustive drug identification universe for United States claims data through 2026-09-21 cannot be fully constructed from the supplied evidence. The supplied documents identify several Acute Lymphoblastic Leukemia-related HCPCS therapy codes and their drug descriptions, but they do not provide NDC identifiers, manufacturers or labelers, package presentations, biosimilar relationships, multi-source generic considerations, or exhaustive pull methodology. The documents identify HCPCS code Q2058 for obecabtagene autoleucel, HCPCS code J9039 for blinatumomab, and HCPCS code C9028 for inotuzumab ozogamicin. No document contains representative NDCs, package configurations, manufacturer mappings, biosimilar linkage data, or generic sourcing considerations. The supplied documents identify several principal Acute Lymphoblastic Leukemia (ALL) therapies relevant to relapsed/refractory or pediatric ALL treatment contexts, including “blinatumomab,” “inotuzumab,” and “PEGasparaginase.” However, the documents do not provide any NDC identifiers, manufacturer or labeler mappings, package presentations, biosimilar relationships, multi-source generic considerations, or exhaustive claims-based pull methodologies. Therefore, an exhaustive United States claims-data drug identification universe through 2026-09-21 cannot be constructed from these documents alone.

Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGYUS Food and Drug AdministrationJournal of the National Comprehensive Cancer Network : JNCCNAmerican journal of hematologyShorla Oncology Inc.,National Library of Medicine (DailyMed)CMS HCPCS Release FilesBRISTOL MYERS SQUIBBBluePoint LaboratoriesTakeda Pharmaceuticals America, Inc.Biocon Pharma Inc.Alembic Pharmaceuticals LimitedApotex CorpSun Pharmaceutical Industries, Inc.FDA Purple BookPrasco LaboratoriesNovartis Pharmaceuticals CorporationE.R. Squibb & Sons, L.L.C.TAKEDA PHARMS USAHospira, Inc.U.S. National Library of MedicineAlembic Pharmaceuticals Inc.Aurobindo Pharma LimitedPfizer Laboratories Div Pfizer IncAmneal Pharmaceuticals LLCDr.Reddy's Laboratories IncSANDOZHikma Pharmaceuticals USA Inc.Sandoz IncBlood advancesTherapeutic drug monitoring

What are the standard adult dosing, route and administration considerations for the principal ALL agents?

The documents provide limited dosing and administration details for some therapies used in acute lymphoblastic leukemia (ALL), but they do not comprehensively describe all principal ALL therapies, complete cycle structures, or line-of-therapy identification patterns through 2026-09-21. For mercaptopurine used in ALL maintenance therapy, the labeling states that the "recommended starting dose of mercaptopurine oral suspension is 1.5 mg/kg to 2.5 mg/kg (50 mg/m 2 to 75 mg/m 2 ) orally once daily as part of combination chemotherapy maintenance regimen," with dose adjustment based on neutrophil counts and myelosuppression. The same source specifies administration considerations including oral suspension handling, dosing interval adjustments in renal impairment, and administration instructions. For imatinib in relapsed or refractory Philadelphia chromosome positive ALL, the document confirms the indication in adult patients but does not provide ALL-specific dosing schedules or cycle structures. The asparaginase consensus document states that "asparaginase is an integral component of therapy" in pediatric-inspired regimens for AYA and adult ALL populations and discusses administration barriers including "limited medical facilities and experienced staff to administer and manage pediatric-inspired regimens," but it does not provide standard adult dosing or schedules. The supplied documents describe administration and dosing patterns for select relapsed/refractory ALL therapies used in U.S. practice, including CAR-T products and nelarabine. TECARTUS for adult relapsed/refractory B-cell precursor ALL is administered intravenously after lymphodepleting chemotherapy, with a target dose of "1 × 10 6 CAR-positive viable T cells per kg body weight, with a maximum of 1 × 10 8 CAR-positive viable T cells," and requires premedication, identity verification, and tocilizumab availability before infusion. Nelarabine for relapsed/refractory T-ALL/T-LBL in adults is given as "1,500 mg/m² administered intravenously over 2 hours on Days 1, 3, and 5 repeated every 21 days," with discontinuation for neurologic toxicity grade 2 or greater and possible dose delays for hematologic reactions. KYMRIAH is identified as a CD19-directed autologous T-cell immunotherapy for "patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse," administered as an "intravenous infusion," but the supplied excerpt does not provide detailed adult ALL dosing schedules because the indication is pediatric/young adult only. The documents provide limited dosing and administration information for therapies used in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), specifically imatinib and dasatinib product identification. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The supplied text does not provide adult ALL-specific standard dosing schedules, cycle structures, or administration setting guidance for imatinib, but it does describe oral daily dosing patterns in related leukemia studies: “patients were treated initially with 400 mg daily” with “Dose escalations ... from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily.” For dasatinib (SPRYCEL), the documents identify the dosage forms and oral route through “SPRYCEL TABLET ORAL” products with strengths including “20MG,” “50MG,” “70MG,” “80MG,” “100MG,” and “140MG,” but no ALL-specific dosing schedules or regimen structures are provided. The supplied documents provide dosing and administration details only for clofarabine in relapsed/refractory acute lymphoblastic leukemia, and specifically state that it is indicated for pediatric patients rather than all adult ALL therapies used in U.S. practice. Clofarabine is described as being administered "52 mg/m 2 as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle," with cycles repeated "approximately every 2 to 6 weeks" and subsequent cycles given "no sooner than 14 days from the starting day of the previous cycle and provided the patient’s ANC is ≥ 0.75 × 10 9 /L." The documents also describe claim-relevant administration considerations including supportive care with "intravenous fluids, antihyperuricemic treatment, and alkalinize urine," avoidance of administering other medications through the same IV line, monitoring during administration, and renal dose reduction "by 50% in patients with creatinine clearance (CrCL) between 30 mL/min and 60 mL/min." No standard adult dosing patterns, adult line-of-therapy structures, or comprehensive ALL regimens through 2026-09-21 are provided in the supplied records. The documents identify methotrexate as a therapy used in acute lymphoblastic leukemia (ALL) and state that it is administered as part of combination chemotherapy regimens, but they do not provide complete adult ALL regimen dosing schedules or cycle structures. The methotrexate labeling states that for neoplastic diseases clinicians should "Refer to the prescribing information for disease specific dosing recommendations" and that "Methotrexate Injection is used as part of a multi-drug regimen." Administration considerations for intermediate- and high-dose methotrexate include leucovorin rescue, daily monitoring, intravenous fluids, urine alkalinization, and glucarpidase use for toxic plasma concentrations with delayed clearance. The NCCN guideline excerpt states that ALL treatment recommendations include "risk-stratified treatment approaches" and that "patients be treated at specialized centers with expertise in the management of ALL." A claim-relevant cellular therapy code is also identified for tisagenlecleucel as "up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." The supplied documents provide limited information on dosing patterns and administration considerations for certain Acute Lymphoblastic Leukemia therapies, but they do not comprehensively describe standard adult regimens, cycle structures, or line-of-therapy identification used in United States clinical practice through 2026-09-21. For PEGasparaginase in ALL11 protocol patients, the documents state that “After the 3 doses of 1500 IU/m 2 administered in induction, standard-risk patients received 1 individualized dose and medium-risk patients 14,” and also describe a “continuous PEGasparaginase dosing schedule” with individualized dose reductions targeting trough activity levels. For CAR-T cell therapy in relapsed/refractory B-ALL, the documents describe the “bridging period between leukapheresis and CAR-T-cells reinfusion” as a treatment consideration but explicitly note that “there is currently no available guidelines.” For nelarabine (Arranon), the documents identify the product as “INJECTION INTRAVENOUS” with active ingredient concentration “NELARABINE 5 mg/mL,” but no adult dosing schedule or cycle information is provided. The documents provide adult dosing and administration information for doxorubicin used in acute lymphoblastic leukemia, but they do not comprehensively enumerate all principal ALL therapies used in United States clinical practice through 2026-09-21. For doxorubicin, the labeling states that for “Metastatic Disease, Leukemia, or Lymphoma” the “recommended dose of doxorubicin when used as a single agent is 60 to 75 mg/m 2 intravenously every 21 days,” and “when administered in combination with other chemotherapy drugs, is 40 to 75 mg/m 2 intravenously every 21 to 28 days.” Administration guidance specifies intravenous administration, including that clinicians should “Administer doxorubicin intravenously over 3 to 10 minutes” through “a central intravenous line or a secure and free-flowing peripheral venous line.” The documents also include claim-relevant cycle and exposure considerations such as “Cumulative doses above 550 mg/m 2 are associated with an increased risk of cardiomyopathy” and that lower doses or longer intervals may be considered for “heavily pretreated patients, elderly patients, or obese patients.” The supplied documents only partially address adult therapy administration patterns for Acute Lymphoblastic Leukemia (ALL) in U.S. For Philadelphia chromosome-positive (Ph+ ALL), the FDA labeling states that SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and trial dosing exposures included “starting dosage 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily.” The labeling also reports treatment duration information for lymphoid blast disease, including that “the median duration of treatment with SPRYCEL 140 mg once daily was ... 3 months (range 0.1–10 months) for lymphoid blast CML.” Separately, HCPCS coding documentation identifies blinatumomab as an injectable therapy using “HCPCS code J9039” defined as “Injection, blinatumomab, 1 microgram.” The documents do not provide complete standard adult dosing schedules, cycle structures, routes, line-of-therapy algorithms, or administration-setting details for the principal ALL regimens used through 2026. The supplied documents identify limited administration and claim-relevant information for Acute Lymphoblastic Leukemia (ALL) therapies, but they do not provide comprehensive standard adult dosing patterns, schedules, or cycle structures through 2026-09-21. Methotrexate Injection is indicated for ALL "as part of a combination chemotherapy regimen" and is labeled "for intravenous, intramuscular, subcutaneous, or intrathecal use," with additional administration considerations including preservative-free formulations for intrathecal use and restrictions related to benzyl alcohol-containing formulations. Brexucabtagene autoleucel HCPCS entries describe a "per therapeutic dose" administration with "up to 200 million autologous anti-cd19 car positive viable t cells" and include "leukapheresis and dose preparation procedures," which are claim-relevant administration components. The documents do not provide standard adult dose amounts, treatment schedules, line-of-therapy definitions, or cycle timing structures for these therapies. The documents identify several therapies used in Acute Lymphoblastic Leukemia and provide limited administration-related information through HCPCS descriptors and one FDA label, but they do not provide comprehensive standard adult dosing, schedules, or cycle structures. HCPCS files identify injectable products including blinatumomab, inotuzumab ozogamicin, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, rituximab, and CAR-T products including tisagenlecleucel and brexucabtagene autoleucel. The dasatinib label states that "DASATINIB tablets, for oral use" are indicated for "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy." CAR-T administration considerations are partially described because tisagenlecleucel HCPCS language specifies "including leukapheresis and dose preparation procedures, per infusion," and brexucabtagene autoleucel is described as "per therapeutic dose." The supplied documents identify doxorubicin as a therapy used in acute lymphoblastic leukemia and provide adult dosing, administration route, schedules, and some administration considerations, but they do not comprehensively cover all principal therapies used in United States clinical practice through 2026-09-21. For leukemia or lymphoma, doxorubicin is described as a single agent at "60 to 75 mg/m 2 intravenously every 21 days" or in combination therapy at "40 to 75 mg/m 2 intravenously every 21 to 28 days." Administration details include intravenous injection through "a central intravenous line or a secure and free-flowing peripheral venous line," with administration "over 3 to 10 minutes," and continuous infusion "only through a central catheter." The documents also describe cycle structure and claim-relevant modifications, including treatment on "day 1 of each 21 day treatment cycle" for "a total of four cycles," dose reductions for hepatic impairment, and cycle delays until recovery of blood counts. The supplied documents identify only limited therapy and administration information for acute lymphoblastic leukemia (ALL). Methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” and the formulation is specified as “METHOTREXATE tablets, for oral use.” The ASH 2026 guideline document for relapsed/refractory ALL states that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” However, the documents do not provide standard adult dosing, administration schedules, cycle structures, or detailed claim-relevant dosing patterns through 2026-09-21. The supplied documents do not provide standard adult dosing, administration routes, schedules, cycle structures, or detailed claim-relevant administration patterns for principal acute lymphoblastic leukemia therapies in United States clinical practice through 2026-09-21. The documents do state that treatment regimens differ between pediatric-inspired and adult-inspired approaches, and that pediatric-inspired regimens containing asparaginase are recommended frontline therapy for adolescents and young adults. The materials also note supportive care requirements, use of targeted agents in frontline therapy, and consideration of allogeneic hematopoietic stem cell transplantation in selected higher-risk patients, but they do not specify drug-level dosing schedules or administration details needed for regimen identification from claims. The supplied documents provide claim-relevant adult dosing, administration route, schedule, cycle structure, and administration-setting considerations for blinatumomab (BLINCYTO) and inotuzumab ozogamicin (BESPONSA) used in acute lymphoblastic leukemia. BLINCYTO is administered intravenously and includes hospitalization and steroid premedication requirements tied to treatment cycles for MRD-positive and relapsed/refractory B-cell precursor ALL. BESPONSA is administered by intravenous infusion with cycle-specific dosing on Days 1, 8, and 15, response-dependent cycle lengths, and mandatory corticosteroid, antipyretic, and antihistamine premedication. The documents do not provide comprehensive dosing and regimen details for all principal ALL therapies used in U.S. clinical practice through 2026-09-21. The documents identify certain Acute Lymphoblastic Leukemia (ALL) therapies and limited administration-related details, but they do not provide comprehensive adult regimen dosing, schedules, cycle structures, or line-of-therapy patterns through 2026-09-21. Blinatumomab and inotuzumab ozogamicin are identified in HCPCS coding as injectable products with billing units of "1 mcg" and "0.1 mg" respectively. Methotrexate tablets are identified for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen," but no ALL-specific adult maintenance dosing schedule, route timing, or cycle structure is provided in the supplied documents. The supplied documents identify several therapies used in Acute Lymphoblastic Leukemia (ALL), including methotrexate formulations, blinatumomab, inotuzumab ozogamicin, rituximab, tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel. The documents also mention transplantation approaches and post-transplant tyrosine kinase inhibitor maintenance strategies for Philadelphia chromosome positive ALL. However, the documents do not provide the requested standard adult dosing patterns, administration routes, treatment schedules, cycle structures, administration settings, or claim-relevant dosing details needed for regimen or line-of-therapy identification. The supplied documents identify HCPCS-coded therapies relevant to Acute Lymphoblastic Leukemia claims and provide limited administration-unit information, but they do not provide standard adult dosing patterns, schedules, cycle structures, line-of-therapy positioning, or administration-setting guidance. Inotuzumab ozogamicin is identified as an injectable product with HCPCS unit definition "0.1 mg." Obecabtagene autoleucel is identified as a CAR-positive viable T-cell therapy with dosing described as "up to 400 million cd19 car-positive viable t cells," including "leukapheresis and dose preparation procedures," and billed "per therapeutic dose" or "per infusion." The supplied documents identify several Acute Lymphoblastic Leukemia therapies and limited administration characteristics, but they do not provide standard adult dosing schedules, cycle structures, line-of-therapy rules, or administration-setting guidance. Iclusig (ponatinib hydrochloride) is described as an oral film-coated tablet with a 10 mg strength presentation, and SPRYCEL (dasatinib) is described as an oral tablet with a 140 mg strength presentation. The HCPCS entry identifies imatinib as "Imatinib 100 mg." No document provides treatment schedules, cycle timing, dose modifications, or claim-relevant regimen construction details. The supplied documents do not provide comprehensive United States adult ALL regimen details such as standard dosing, schedules, cycle structures, or administration-setting considerations. One FDA Drugs@FDA entry identifies ICLUSIG formulations and route relevant to ALL-related therapy identification: it lists "ICLUSIG TABLET ORAL" products with multiple strengths. A Chinese adult ALL guideline states that "systematic treatment regimens" and immunotherapies including antibodies and CAR-T products are used in adult ALL clinical practice, but it does not specify adult dosing patterns or cycle structures. The supplied documents identify dasatinib as an oral tablet product with multiple tablet strengths that may be relevant to Acute Lymphoblastic Leukemia regimen identification in claims data. The documents provide packaging, dosage strength, and oral route information for 20 mg, 50 mg, and 70 mg film-coated tablets. However, the documents do not provide standard adult dosing, treatment schedules, cycle structures, administration setting considerations, line-of-therapy usage, or claim-relevant dosing patterns for ALL treatment through 2026-09-21. The supplied documents identify dasatinib (SPRYCEL and generic dasatinib) as an oral tablet product used in U.S. practice, with available tablet strengths including 50 mg, 70 mg, and 140 mg. The documents also identify packaging quantities that may be relevant for claim-level regimen identification, including bottles containing 30 or 60 tablets. The supplied document identifies Arranon (nelarabine) as an intravenous injection product used in U.S. clinical practice packaging and formulation information. It specifies the formulation strength as "NELARABINE 5 mg/mL" and the administration route as "INJECTION INTRAVENOUS." The document does not provide standard adult dosing, treatment schedules, cycle structure, administration setting considerations, or claim-relevant dosing patterns for Acute Lymphoblastic Leukemia regimens or line-of-therapy identification. The supplied documents identify Iclusig (ponatinib hydrochloride) as an oral tablet product with multiple tablet strengths that could support claim-based identification of therapy exposure. The documents provide packaging and strength information for 15 mg, 30 mg, and 45 mg tablet presentations, but they do not provide standard adult dosing, treatment schedules, cycle structures, line-of-therapy positioning, or administration-setting considerations for Acute Lymphoblastic Leukemia treatment through 2026-09-21. The supplied documents identify dasatinib products used in U.S. practice for Acute Lymphoblastic Leukemia and establish oral tablet administration and available tablet strengths, but they do not provide standard adult dosing, treatment schedules, cycle structures, line-of-therapy use, or administration-setting considerations. The records show SPRYCEL and generic dasatinib as oral tablet products with 80 mg and 100 mg strengths packaged in bottles containing 30 tablets. The supplied documents identify certain Acute Lymphoblastic Leukemia therapies and their administration forms/routes, but they do not provide standard adult dosing, schedules, cycle structures, line-of-therapy use, or administration-setting considerations. Dasatinib is identified as an oral tablet product with strengths including 20 mg and 50 mg. Clofarabine is identified as an intravenous injection product with concentration 1 mg/mL in a single-dose vial. The supplied documents identify IMKELDI as an oral imatinib formulation relevant to leukemia treatment identification, but they do not provide standard adult dosing, schedules, cycle structures, line-of-therapy criteria, or administration setting considerations for Acute Lymphoblastic Leukemia. The documents only specify that IMKELDI is an "imatinib oral" "SOLUTION ORAL" product with strength "80 mg/mL" and marketing details for the United States.

Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematologyNational Library of Medicine (DailyMed)Alembic Pharmaceuticals LimitedSun Pharmaceutical Industries, Inc.BRISTOL MYERS SQUIBBAmneal Pharmaceuticals LLCDr.Reddy's Laboratories IncHospira, Inc.Journal of the National Comprehensive Cancer Network : JNCCNU.S. National Library of MedicineTherapeutic drug monitoringBulletin du cancerNovartis Pharmaceuticals CorporationUS Food and Drug AdministrationPfizer Laboratories Div Pfizer IncCMS HCPCS Release FilesBluePoint LaboratoriesBlood advancesAurobindo Pharma LimitedBryant Ranch PrepackAlembic Pharmaceuticals Inc.HOSPIRAFDA Purple BookTakeda Pharmaceuticals America, Inc.E.R. Squibb & Sons, L.L.C.Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiTAKEDA PHARMS USABiocon Pharma Inc.Sandoz IncPrasco LaboratoriesShorla Oncology Inc.,SHORLA ONCOLOGY

What are the common reasons for treatment discontinuation and dose modification in ALL?

The supplied documents report treatment interruption and discontinuation drivers primarily for the bispecific T-cell engager blinatumomab (BLINCYTO). The label states that "Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO" and directs clinicians to "Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended," while "Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS)" also require clinicians to "Interrupt or discontinue BLINCYTO as recommended." The label additionally describes interruption-related administration patterns that could be inferable in claims, including "re-initiations (e.g., if treatment is interrupted for 4 or more hours)," hospitalization recommendations at cycle starts, and fixed treatment-free intervals consisting of "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval." The NCI PDQ document describes major ALL therapy classes used in induction, including "combination chemotherapy with prednisone, vincristine, and an anthracycline," with optional additions such as "asparaginase or cyclophosphamide," and notes regimen modification through "omission of L-asparaginase" and rapid relapse after imatinib-containing therapy, but it does not provide explicit claims-based discontinuation definitions, dose-reduction algorithms, or switching rules across ALL therapies. The supplied document addresses an anthracycline therapy class used in Acute Lymphoblastic Leukemia and reports discontinuation and dose-modification drivers centered on cardiomyopathy, hepatic impairment, infusion complications, and severe myelosuppression. Reported discontinuation drivers include: “Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy” and “Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection; discontinue Doxorubicin Hydrochloride Injection.” Dose reduction patterns are described for hepatic impairment, including “1.2–3 mg/dL 50%” and “3.1–5 mg/dL 75%,” and interruption/administration modification signals include “Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur” and “Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation.” The document also reports severe toxicity events that could be inferable in administrative claims data, including “serious infection, septic shock, requirement for transfusions, hospitalization, and death,” cardiomyopathy monitoring, and hospitalization-related complications, but it does not provide explicit claims-based line-of-therapy discontinuation algorithms, switching definitions, or coverage of other major ALL therapy classes. The supplied documents report toxicity-driven dose reduction and interruption signals for several ALL therapy classes, but they do not provide a comprehensive cross-class analysis of discontinuation, switching, or claims-based line-of-therapy algorithms through 2026-09-21. For vincristine-based therapy, co-administration with azoles was associated with increased neurotoxicity, CNS toxicity, intensive care use, and dose reduction; the text states that "Because of severe toxicities, vincristine treatment was significantly reduced (50% of normal dose) in several patients." For inotuzumab ozogamicin (BESPONSA), the label reports hepatotoxicity/VOD and liver test elevations as drivers of "dosing interruption, dose reduction, or permanent discontinuation," and notes that treatment cycles "may be extended up to 28 days" to allow recovery from toxicity. The documents do not define claims-based discontinuation rules, switching algorithms, or specific administrative claims indicators for line-of-therapy construction, although observable claims proxies inferable from the text could include ICU treatment, infusion timing extensions, and reduced administered dose intensity. The document describes major ALL therapy classes and some treatment-modification contexts, but it does not report administrative-claims algorithms for discontinuation, interruption, switching, or line-of-therapy construction. It states that ALL treatment commonly includes "Long-term chemotherapy (chemo)" and that "Other types of drugs, such as targeted drugs or immunotherapy, are sometimes part of treatment as well," with stem cell transplant as another option. Dose modification is mentioned for older or medically frail patients, where they "might not be able to tolerate an intensive induction regimen" and "reduced doses of many of these same drugs might be used." Toxicity- or tolerability-related treatment adjustment is indirectly referenced through statements that induction therapy is intensive, may require hospitalization, and that "serious infections or other complications can occur," but the document does not define discontinuation, interruption, switching rules, or claims-observable indicators through 2026-09-21. The supplied document only reports treatment modification and interruption drivers for doxorubicin-containing chemotherapy used in conditions including acute lymphoblastic leukemia, and it does not cover all major ALL therapy classes or comprehensive claims-based line-of-therapy algorithms through 2026-09-21. Reported discontinuation/interruption or dose-modification drivers include cardiotoxicity risk management, neutropenic fever/infection, delayed blood count recovery, unresolved nonhematologic toxicities, hyperbilirubinemia, and infusion-related extravasation concerns. Observable or inferable administrative claims signals from these events may include delayed treatment cycles, reduced administered dose intensity, therapy restarts after gaps, and supportive care or complication coding associated with neutropenic fever/infection or toxicity management, but the document does not explicitly define claims-based discontinuation rules. The supplied documents report that maintenance therapy for ALL commonly involves oral 6-mercaptopurine (6-MP) and methotrexate (MTX), and that these agents are associated with tolerability-driven dose modifications and adverse events. One study specifically aimed "to describe real-world dose adjustments of MTX and 6-MP during the maintenance therapy in young adults" and noted that these oral therapies "frequently cause adverse events." The documents do not provide comprehensive information on treatment discontinuation drivers, interruption patterns, therapy switching signals across all major ALL therapy classes, or validated administrative-claims definitions for discontinuation and line-of-therapy construction through 2026-09-21.

National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer IncJournal of Clinical OncologyAmerican Cancer SocietyUS Food and Drug AdministrationOpen web

What adverse events are most clinically significant for ALL therapies?

The documents identify several major ALL therapy classes and associated clinically significant adverse events. Conventional induction chemotherapy regimens for adult ALL include "prednisone, vincristine, and an anthracycline," with some regimens adding "asparaginase or cyclophosphamide." BLINCYTO (blinatumomab), a "bispecific CD19-directed CD3 T-cell engager," carries boxed warnings for "Cytokine Release Syndrome (CRS), which may be life-threatening or fatal" and "Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal," with recommendations to "Interrupt or discontinue BLINCYTO" and hospitalization recommendations during early treatment cycles. BESPONSA (inotuzumab ozogamicin), a "CD22-directed antibody and cytotoxic drug conjugate," is associated with "Hepatotoxicity, including fatal and life-threatening VOD," "higher post-HSCT non-relapse mortality," "Myelosuppression," "Infusion Related Reactions," and "QT Interval Prolongation"; the label states that liver test elevations "may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA" and that treatment should be "Permanently discontinue[d]" if VOD occurs. The supplied documents do not directly describe United States claims-data analyses through 2026-09-21 or explicitly define claims-identifiable adverse-event markers beyond hospitalization recommendations, treatment interruption/discontinuation instructions, dose modifications, and transplant-associated mortality risks. The supplied documents only address the anthracycline class represented by doxorubicin in ALL therapy, not all major ALL therapy classes. For doxorubicin, clinically significant adverse events include “Cardiomyopathy,” “Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS),” “Extravasation and Tissue Necrosis,” and “Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death.” The labeling also describes treatment modification and escalation patterns tied to adverse events, including that “Patients in the NSABP B-15 study could have dose modifications of AC to 75% of the starting doses for neutropenic fever/infection,” and that “the next cycle of treatment cycle was delayed until the absolute neutrophil count (ANC) was ≥1000 cells/mm3 and the platelet count was ≥100,000 cells/mm3 and nonhematologic toxicities had resolved.” Claims-identifiable markers explicitly described include hospitalization, transfusion requirement, septic shock, neutropenic fever/infection, skin grafting, and wide excision surgery associated with extravasation injuries. The document identifies major ALL therapy classes as "chemotherapy (chemo)," "targeted drugs," and "immunotherapy," noting that "For some people, a stem cell transplant might also be an option." During induction chemotherapy, treatment is described as intensive, and the document states that patients "may spend some or much of this time in the hospital, because serious infections or other complications can occur" and that "Sometimes, complications can be life-threatening." The text also describes treatment modification patterns based on tolerability, stating that older patients or those with serious health conditions "might not be able to tolerate an intensive induction regimen," so "reduced doses of many of these same drugs might be used" and "Other options could include treatment with the antibody-drug conjugate inotuzumab ozogamicin or a steroid drug such as dexamethasone or prednisone." The supplied document does not provide claims-data methodologies, adverse-event coding markers, discontinuation patterns, escalation patterns, or detailed toxicity profiles by therapy class through 2026-09-21. The supplied documents identify major ALL therapy categories and some general disease- and treatment-related clinical issues, but they do not provide a detailed mapping of clinically significant adverse events by therapy class, nor claims-based hospitalization, discontinuation, escalation, or treatment-modification patterns through 2026-09-21. The National Cancer Institute document states that “Previous chemotherapy and exposure to radiation may increase the risk of developing ALL,” and that “Leukemia may affect red blood cells, white blood cells, and platelets.” The Medscape reference lists major treatment components including “Induction Chemotherapy,” “Consolidation Therapy,” “Maintenance Therapy,” “CNS Prophylaxis,” and “Treatment of Ph Chromosome–Positive ALL,” but does not describe associated toxicities, hospitalization triggers, or claims-identifiable adverse-event markers. No supplied document reports claims-data analyses, hospitalization-associated adverse events, treatment discontinuation patterns, or escalation patterns tied to ALL therapy adverse events.

National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer IncUS Food and Drug AdministrationAmerican Cancer SocietyOpen web

How is treatment response and measurable residual disease assessed in ALL?

The supplied document indicates that the CIBMTR Disease Classification Form contains an Acute Lymphoblastic Leukemia section and captures disease-specific response information for hematopoietic cell transplantation reporting, including “disease type, subtype, transformations, cytogenetic and molecular markers, disease-specific laboratory results, staging, and disease status.” It also states that “Status at Transplantation” should be determined using CIBMTR manual guidelines because “there are many interpretations of disease response criteria,” and that “a majority of the disease response criteria are established by an international working group.” The document further specifies that diagnosis dates may derive from “bone marrow or tissue biopsy” or “pathological or laboratory assessment.” However, the document does not provide explicit Acute Lymphoblastic Leukemia response milestone definitions, measurable residual disease (MRD) criteria, MRD laboratory testing methods, monitoring schedules, or any discussion of what is directly observable, partially inferable, or absent in United States administrative claims data through 2026-09-21. The documents describe treatment-response evaluation in adult acute lymphoblastic leukemia (ALL) primarily through remission and survival outcomes after induction and postremission therapy. Reported response milestones include “complete response rates that range from 60% to 90%” and “436 achieved complete remission (78% +/- 2% for DNR v 74% +/- 3% for ZRB; P = .3),” as well as monitoring outcomes such as “disease relapse at a median of 58 days after the start of therapy,” “median duration of 2.2 months,” and “3-year disease-free survival.” Laboratory and pathology assessment evidence includes the existence of a “Bone marrow Pathology biopsy report” defined by LOINC code 33721-2. However, the supplied documents do not describe measurable residual disease (MRD) criteria, MRD laboratory methods, flow cytometry, molecular assays, PCR, next-generation sequencing, or any explicit administrative claims observability framework; therefore, direct versus inferable claims-data observability for these components cannot be determined from the documents. The document describes treatment response assessment criteria for relapsed or refractory CD22-positive B-cell precursor ALL using complete remission (CR), complete remission with incomplete hematologic recovery (CRi), bone marrow blast percentage, peripheral blood leukemic blasts, peripheral blood count recovery, and extramedullary disease resolution. It also references measurable residual disease (MRD) negativity as a treatment milestone relevant to hematopoietic stem cell transplant (HSCT) planning, but it does not describe MRD laboratory testing methods or monitoring procedures. The document includes laboratory and clinical monitoring elements such as bone marrow assessment, absolute neutrophil count (ANC), platelet count, bilirubin, AST/ALT, and peripheral blast count thresholds. The supplied source does not address administrative claims data observability, so no direct evidence is available regarding which response or MRD components are directly observable, partially inferable, or absent in claims data through 2026-09-21. The supplied documents provide only limited information relevant to treatment response evaluation in Acute Lymphoblastic Leukemia. One document identifies a bone marrow biopsy-related assessment element through the LOINC entry "Guidance for biopsy of Bone marrow," indicating that bone marrow biopsy procedures are represented in clinical terminology systems. Another document references the topic "Novel Therapies for Childhood Acute Lymphoblastic Leukemia" but does not provide details on response assessment criteria, measurable residual disease testing methods, monitoring procedures, response milestone definitions, or administrative claims observability limitations. The documents describe treatment response assessment in acute lymphoblastic leukemia (ALL) primarily through measurable residual disease (MRD) testing and risk stratification. MRD positivity is described as “commonly defined as at least 1 leukemia cell in 10,000 normal cells (expressed as 10-4)” and FDA-approved therapeutic decision making included “first or second complete remission with MRD greater than or equal to 0.1%.” Reported MRD laboratory methods include flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS), with monitoring performed on bone marrow aspirates and in some settings peripheral blood; flow cytometry requires “the first pull of bone marrow aspiration,” PCR is used commonly for “BCR/ABL gene rearrangements,” and NGS can monitor “immunoglobulin heavy chain receptor rearrangements or T-cell receptors.” The supplied documents do not directly address administrative claims data observability, but they describe clinical and laboratory components that are procedure- and result-based rather than billing-based, so direct claims observability of MRD status, assay sensitivity thresholds, immunophenotype findings, and remission definitions is not explicitly documented in the sources.

CIBMTRNational Cancer InstituteU.S. National Library of MedicineJournal of Clinical OncologyNational Library of Medicine (DailyMed)Default Digital Object GroupOpen web

What is the role of allogeneic transplant and CAR-T as end states in ALL?

The supplied document positions BLINCYTO within several Acute Lymphoblastic Leukemia (ALL) treatment phases, including measurable residual disease treatment, relapsed/refractory therapy, and consolidation therapy. The document states that BLINCYTO is indicated for “CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%,” for “Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL),” and for “CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.” The document also describes induction, consolidation, and “continued therapy” cycles for relapsed/refractory disease. However, the supplied material does not describe the positioning of allogeneic hematopoietic stem cell transplant or CAR-T therapy within the ALL treatment journey, does not define terminal pathway states or post-treatment outcomes after those therapies, and does not provide claims-based procedure identification methods or coding approaches through 2026-09-21. The supplied document positions hematopoietic stem cell transplant (HSCT) as a downstream treatment pathway for patients with relapsed or refractory CD22-positive B-cell precursor ALL who respond to therapy with inotuzumab ozogamicin. The label states, “For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles,” with a possible third cycle if remission and MRD negativity are not achieved, indicating use as a bridge-to-transplant or consolidation approach before HSCT. The document also describes post-transplant outcome states and risks, including “Hepatotoxicity, including fatal and life-threatening VOD” and “higher post-HSCT non-relapse mortality rate.” The supplied material does not address CAR-T therapy positioning, salvage versus terminal pathway frameworks across all ALL patients in the United States, or claims-based procedure identification methods through 2026-09-21. The documents position allogeneic bone marrow transplant within the treatment journey for adult ALL as a consideration after induction or other chemotherapy responses because “remissions are generally short with conventional ALL chemotherapy clinical trials.” One document identifies tisagenlecleucel specifically as “a CAR-T cell therapy” used “for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States,” which places CAR-T therapy in the relapsed/refractory setting. The supplied documents do not describe transplant or CAR-T as consolidation, salvage, or terminal pathway states in broader U.S. ALL populations, do not describe post-treatment outcome states or bridge pathways, and do not provide claims-based procedure identification methods or coding approaches through 2026-09-21. The documents position CAR-T therapy for ALL primarily in the relapsed or refractory setting and describe bridging chemotherapy before infusion, while also discussing survivorship, toxicities, infections, and death after therapy as outcome states. One document states that “Three CAR T-cell products have been approved by the FDA to treat patients with relapsed or refractory B-cell ALL,” and another states that “While the CAR T cells are being manufactured, patients may receive additional chemotherapy to prevent their disease from progressing.” The supplied documents also describe post-treatment states including “short- and long-term side effects and toxicities,” “Infections,” survivorship, and “why some patients die from a CAR T-related toxicity.” The supplied documents do not provide a positioning for allogeneic hematopoietic stem cell transplant as consolidation, salvage, or terminal therapy, and they do not provide claims-based procedure identification methods or coding algorithms through 2026-09-21.

National Library of Medicine (DailyMed)Journal of Clinical OncologyNational Cancer InstituteOpen web

What monitoring cadence is recommended during and after ALL therapy?

The document states that for adult ALL, “Treatment for ALL typically lasts for at least 2 years,” and that after treatment ends patients require “frequent follow-up exams and tests for at least several years,” which “will probably be every month or so at first, then less often as time passes.” Monitoring activities described include clinical examinations, symptom review, “blood tests, bone marrow exams, or other tests to look for treatment side effects or signs of leukemia,” as well as survivorship planning for “follow-up exams and tests,” “screening tests for other types of cancer,” and “tests to look for long-term health effects from your leukemia or its treatment.” The document also notes ongoing toxicity and side-effect monitoring, stating that “Almost any cancer treatment can have side effects,” and patients should report “any changes or problems.” The supplied document does not describe which monitoring activities can be captured or inferred from administrative claims data, and it does not provide detailed active-treatment monitoring cadence beyond treatment duration. The supplied document describes components of active treatment for adult Acute Lymphoblastic Leukemia (ALL) but does not provide recommended monitoring cadence during active treatment, remission surveillance, or post-treatment follow-up, and it does not discuss which monitoring activities can be captured in administrative claims data. The document states that induction therapy commonly uses multiagent chemotherapy regimens and mentions supportive care measures and hematopoietic growth factors during remission-induction therapy. No laboratory surveillance schedules, imaging frequency, toxicity-monitoring cadence, remission follow-up intervals, or claims-based monitoring definitions are provided in the supplied text. The supplied document does not provide recommendations for monitoring cadence during active treatment, remission surveillance, or post-treatment follow-up for Acute Lymphoblastic Leukemia in the United States. It also does not describe laboratory surveillance frequency, imaging schedules, toxicity monitoring cadence, or administrative claims methodologies. The only monitoring-related activity identifiable from the document is the existence of a LOINC-coded bone marrow pathology biopsy report: LOINC code 33721-2 is defined as "Bone marrow Pathology biopsy report." The supplied documents describe ALL management as prolonged and involving ongoing outpatient monitoring, but they do not provide specific recommended monitoring cadences for active treatment, remission surveillance, or post-treatment follow-up in the United States. One document states that "Over the course of 2 to 3 years, patients undergo treatment for induction, consolidation, maintenance, and possibly hematopoietic cell transplantation" and that outpatient management includes "adherence to medications, ambulatory treatment, and monitoring." The documents also describe toxicity and adverse-event monitoring during outpatient therapies, including that "nurses can provide close monitoring and rapid recognition of adverse events" for CAR-T therapy and that blinatumomab may continue as "home infusion therapy." These activities could potentially correspond to administrative claims-captured events such as outpatient visits, ambulatory treatments, home infusion services, medication-related encounters, and hospitalization periods, but the documents do not explicitly define claims-based capture methods, laboratory surveillance schedules, imaging schedules, or remission follow-up intervals.

American Cancer SocietyNational Cancer InstituteU.S. National Library of MedicineOpen web

What are the principal unmet needs in ALL treatment in the United States?

Not answered from the sources consulted.

Where do guideline recommendations and FDA labels diverge in ALL?

The supplied document provides limited information relevant to claims-based line-of-therapy definitions in ALL. It describes a claims-based distinction between frontline and second-line asparaginase therapy, specifically defining patients who "switched from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) recombinant Erwinia." The document also identifies that patients were "treated with 1 L asparaginase-containing regimens" and that "35/154 (22.7%) patients switched from 1 L asparaginase to recombinant Erwinia," which may inform regimen classification and sequencing assumptions in retrospective claims analyses. However, the document does not discuss NCCN recommendations, FDA-approved labels, guideline-label discordance, maintenance therapy definitions, off-label sequencing recommendations, combination therapy assumptions, or temporal label changes through 2026-09-21. The supplied document provides limited information relevant to guideline-label discordance and sequencing in Acute Lymphoblastic Leukemia. It states that in adult Philadelphia chromosome-negative B-cell ALL, “Blinatumomab is currently the only targeted agent approved for frontline treatment,” while also describing investigational and emerging frontline use of other targeted therapies such as “frontline inotuzumab (±blinatumomab) plus chemotherapy,” indicating ongoing clinical use patterns beyond clearly described approved frontline labeling. The document also describes blinatumomab use in specific frontline consolidation and MRD-positive CR1 settings, which may affect claims-based line-of-therapy interpretation, but it does not explicitly compare NCCN recommendations with FDA labels, define regimen-classification rules, maintenance definitions, sequencing standards, or temporal label changes. The supplied document does not discuss NCCN recommendations, FDA-approved labels, temporal label changes, maintenance therapy definitions, or claims-based line-of-therapy rules. It does, however, describe uncertainty in adult ALL regimen selection and sequencing, stating that "The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps" and that "In adult ALL there is no standard which drugs to give and how to combine them." The study also distinguishes treatment eligibility by Philadelphia chromosome status, excluding known Ph+ ALL patients and discontinuing protocol treatment if Ph+ disease is later identified.

Journal of medical economicsHematology (Amsterdam, Netherlands)Memorial Sloan Kettering Cancer Center

What real-world evidence gaps exist for ALL treatment sequencing?

Not answered from the sources consulted.

Which ALL clinical concepts are not observable from administrative claims alone?

The documents identify several clinically relevant concepts used in acute lymphoblastic leukemia (ALL) management that depend on molecular testing, remission assessment, relapse assessment, and transplant-related evaluation rather than directly observable claims-based information. These include molecular and cytogenetic subtype information such as “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL),” “ZNF384 fusion transcripts,” “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations.” The documents also reference response and remission states including “first complete response (CR1),” “complete remission (CR),” and “minimal residual disease (MRD)” positivity or negativity assessed by “MFC and RT-qPCR targeting ZNF384 fusion transcripts.” Relapse-related concepts are discussed through outcomes such as “nearly half of patients relapsed within 3 years” and “cumulative incidence of relapse (CIR),” while transplant-related concepts include patients who “underwent allo-HSCT in complete remission (CR)” and “pre-transplant MRD.” However, the supplied documents do not explicitly discuss United States administrative claims data limitations, transplant eligibility criteria, or which concepts are fully versus partially inferable from claims alone. The document indicates that several clinically relevant concepts for B-ALL management depend on biomarker testing, bone marrow evaluation, flow cytometry, NGS monitoring, imaging, or physician assessment rather than routine administrative records alone. Response/remission status and minimal residual disease are defined using terms such as “bone marrow morphologic complete remission,” “flow cytometry measurable residual disease (MRD) negative,” and “NGS MRD negative,” all of which require specialized testing. Relapse risk and relapse monitoring are described as requiring “blood and bone marrow tests,” “NGS monitoring,” and assessment of “functional CART persistence,” while transplant eligibility depends on factors such as donor identification and physician determination of “co-morbidities precluding myeloablative HCT.” The document also references disease-related features requiring detailed clinical assessment, including “extramedullary disease (EMD)” and “central nervous system (CNS) disease,” but it does not directly discuss molecular/cytogenetic status in the context of claims-based observability. The supplied document indicates that accurate acute leukemia diagnosis requires information beyond morphology alone, specifically "flow cytometric immunophenotyping" and assessment of "aberrant antigen expression." The document also notes that morphology can be "challenging in ambiguous cases" and that immunophenotyping enables "more precise lineage assignment." However, the documents do not discuss United States administrative claims data, line-of-therapy construction, QA validation, or whether disease severity markers, molecular/cytogenetic status, response/remission status, relapse timing, transplant eligibility, or minimal residual disease are observable or inferable from claims alone. The supplied documents identify several clinically relevant concepts in Acute Lymphoblastic Leukemia (ALL) that are associated with prognosis, treatment selection, disease spread, and clinical development, but they do not discuss United States administrative claims data or directly state which concepts are unobservable or only partially inferable from claims alone. The documents mention prognosis-related factors, tests examining blood and bone marrow, spread to the central nervous system, and targeted therapeutics development, which are related to disease severity, molecular characterization, and treatment assessment. However, the documents do not specifically address response or remission status, relapse timing, transplant eligibility, or minimal residual disease in the context of claims-based line-of-therapy construction or QA validation.

Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)The Libyan journal of medicineOpen web